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 I 
ABSTRACT 
Background. Deranged metabolism is a hallmark of cancer cells which 
need to sustain uncontrolled cell growth while maintaining a proper energy 
balance. Means to interfere with the cancer-associated metabolic 
alterations to control tumor cell proliferation are actively pursued. Most 
tumors rely on enhanced glucose consumption to supply Krebs cycle 
intermediates (a process called anaplerosis), which are continuously 
diverted to the macromolecular biosynthesis needed by proliferation. 
However, nutrients other than glucose may support anaplerosis in tumors, 
likely depending on the oncogenic mutations present in the particular type 
of cancer. Glutamine (Gln), the most abundant amino acid in blood, is a 
precursor of other amino acids (i.e. asparagine), nucleotides and 
glutathione, and stimulates mTOR. Tumors that rely on Gln instead of 
glucose for anaplerosis exhibit an enhanced requirement for the amino acid 
(“glutamine addiction”); however, reliable markers of “glutamine addiction” 
are still needed; in particular, the role of Glutamine Synthetase (GS), a key 
enzyme of Gln metabolism, has not been yet defined in this context. GS 
expression is known to be regulated at the protein level by intracellular Gln 
content, but, at transcriptional level, its expression is driven by the 
oncogene β-catenin. Consistently, its over-expression is a marker of β-
catenin mutations in hepatocellular carcinoma (HCC), a liver cancer with 
poor prognosis. We have hypothesized that β-catenin-dependent GS 
expression may be a marker of a metabolic drift towards Gln-dependence 
and, hence, of Gln-addiction.  
Aim of the thesis. The purpose of this study is to investigate the effects of 
Gln depletion on human HCC cells so as to verify the hypothesis that β-
catenin-dependent GS expression points to a Gln-addicted phenotype.  
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In addition, the role of GS in the adaptation to Gln depletion of two other 
human cell models has been also assessed so as to achieve a general 
appraisal of the metabolic role of the enzyme under conditions of nutritional 
stress. 
Methods. Gln depletion was achieved with the bacterial enzyme L-
asparaginase (ASNase), a drug employed in the treatment of acute 
lymphoblastic leukemia, and the irreversible GS inhibitor methionine-L-
sulfoximine (MSO). We have evaluated ASNase and MSO effects on cell 
viability and mTOR activity in β-catenin-mutated HCC cell lines, in two GS-
negative human oligodendroglioma cells, and in bone marrow 
mesenchymal stem cells (MSCs). Moreover, ASNase and MSO effects 
were also assessed on HCC xenograft models. 
Results. Gln depletion, obtained with ASNase and MSO, markedly hinders 
the proliferation of β-catenin-mutated, GS-positive, HCC cells in vitro and in 
vivo. The determination of mTOR activity in Gln-depleted HCC cells 
indicated that ASNase markedly inhibits the kinase, while MSO caused its 
paradoxical activation, suggesting that the GS inhibitor may deceive the 
intracellular amino acid sensors that regulate mTOR. ASNase causes 
massive cells death in GS-negative human oligodendroglioma cell lines, 
where MSO is ineffective. On the other hand, MSO prevents the adaptation 
of MSCs to Gln-depletion, suggesting that GS activity may contribute to the 
recently described trophic function of MSCs towards leukemic blasts.  
Conclusions. These results indicate a role of β-catenin mutations in 
promoting Gln addiction in HCC and suggest that pharmacological Gln 
depletion represents a metabolic approach for the therapy of β-catenin-
mutated liver cancers. Moreover, GS activity seems crucial for adaptation 
to Gln shortage, not only in HCC cells, but also in MSCs and 
oligodendroglioma cells. These evidences suggest that GS constitute a 
useful diagnostic tool and/or therapeutic target in selected types of human 
tumors.  
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SOMMARIO 
Introduzione. Le alterazioni metaboliche sono una caratteristica delle 
cellule tumorali, le quali devono sostenere un’attiva proliferazione senza 
incorrere in una carenza energetica. Pertanto, la ricerca di approcci 
metabolici che interferiscono con la crescita tumorale è attivamente 
perseguita. La maggior parte delle cellule tumorali è contraddistinta da un 
aumentato consumo di glucosio, necessario per rifornire il ciclo di Krebs di 
intermedi estratti a scopo biosintetico (anaplerosi). Tuttavia, a seconda 
delle mutazioni oncogeniche presenti nel fenotipo tumorale, altri nutrienti 
oltre al glucosio possono essere utilizzati a scopo anaplerotico. Tra essi 
spicca la glutamina (Gln), il più abbondante amminoacido nel sangue, 
precursore di altri aminoacidi, di nucleotidi e del glutatione nonché 
attivatore di mTOR. Tumori che utilizzano Gln a scopo anaplerotico hanno 
un aumentato fabbisogno di tale aminoacido e vengono perciò definiti 
“glutamine addicted”. Tuttavia non sono ancora stati identificati markers di 
“glutamine addiction” e, in particolare, il ruolo della Glutamina Sintetasi 
(GS), enzima chiave del metabolismo della Gln, non è ancora stato chiarito. 
L’espressione di GS è regolata a livello proteico dalla concentrazione 
intracellulare di Gln, ma, a livello trascrizionale, la sua espressione è 
dovuta all’oncogene β-catenina. Difatti l’iper-espressione di GS è un marker 
diagnostico di mutazione della β-catenina nel carcinoma epatocellulare 
(HCC), un tumore maligno del fegato con prognosi infausta. Pertanto 
l’espressione di GS causata dall’iperattivazione della β-catenina potrebbe 
indicare un metabolismo tumorale dipendente da Gln. 
Scopo della tesi. Lo scopo di questo studio è valutare gli effetti della 
deplezione di Gln in linee umane di HCC, per verificare l’ipotesi che iper-
espressione di GS dovuta a mutazioni di β-catenina possa essere un 
marker di “glutamine addiction”. Inoltre è stato valutato anche il ruolo di GS 
nell’adattamento alla deprivazione di Gln di altri due modelli cellulari umani, 
 IV 
per ottenere una stima generale sul ruolo metabolico dell’enzima in 
condizioni di stress nutrizionale. 
Metodi. La deplezione di Gln è stata ottenuta combinando l’enzima 
batterico L-asparaginasi (ASNase), in uso nella terapia della leucemia 
linfoblastica acuta, con la metionina-L-sulfoximina (MSO), un inibitore 
irreversibile di GS. Sono stati valutati gli effetti di ASNase e MSO sulla 
vitalità cellulare e sulla attività di mTOR in linee tumorali umane di HCC 
mutate in β-catenina (in vitro e in xenografts in modelli murini), in due linee 
di oligodendroglioma umano e in cellule mesenchimali staminali (MSC) 
umane derivate dal midollo osseo di donatori. 
Risultati. Sia in vitro che in vivo, la deplezione di Gln ottenuta tramite 
ASNase e MSO, inibisce marcatamente la proliferazione delle linee cellulari 
mutate in β-catenina e positive per GS. Inoltre, mentre ASNase inibisce 
significativamente l’attività di mTOR, l’aggiunta di MSO, pur causando 
un’ulteriore diminuzione del contenuto intracellulare di Gln, determina 
un’attivazione paradossale della chinasi, suggerendo che l’inibitore di GS 
interagisca con dei sensori per aminoacidi a monte di mTOR. Nei modelli di 
oligodendroglioma umano GS-negativi ASNase causa una massiva morte 
cellulare, mentre l’aggiunta di MSO risulta inefficace. D’altra parte MSO 
previene l’adattamento delle MSC alla deplezione di Gln, suggerendo che 
GS possa contribuire alla funzione trofica, recentemente dimostrata, delle 
MSC nei confronti dei blasti leucemici.  
Conclusioni. I risultati ottenuti indicano un coinvolgimento delle mutazioni di 
β-catenina nel favorire un fenotipo neoplastico dipendente da Gln e 
dimostrano che la deplezione farmacologica di Gln rappresenta un 
approccio metabolico per la terapia dei tumori al fegato caratterizzati da 
mutazioni di β-catenina. Inoltre GS sembra necessaria per l’adattamento 
alla deplezione di Gln in tutti i modelli cellulari testati. Questi risultati 
suggeriscono che GS possa essere un mezzo diagnostico e/o un target 
terapeutico in determinati tipi di tumore. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Metabolism & Cancer 
Alteration in cell metabolism is now considered a hallmark of cancer [1]. 
Cancer cells must cope with the enhanced energy consumption and the 
increased synthesis of macromolecules necessary for support uncontrolled 
cell growth. As a result, the metabolism of tumor tissues differs from that of 
the normal tissue from which cancer arises [2]. The discover that several 
oncogene or oncosuppressor or mutations in metabolic enzymes may 
regulate cancer metabolism [3] boosted the interest on this field and is 
generating a thriving scientific production. Also, targeting rewired 
metabolism may provide useful tools for cancer control.  
 
1.1.1 Metabolic alteration in cancer 
1.1.1.1 The Warburg effect 
It is now assumed that altered glucose metabolism is a common feature of 
cancer cells. Otto Warburg discovered in early 20s that tumor cells 
metabolize large amounts of glucose into lactate even in the presence of 
oxygen [4]. Now, this phenomenon is known as aerobic glycolysis or 
Warburg effect (Fig. 1). 
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Fig. 1 Anaerobic glycolysis and Warburg effect (from [5]). 
 
Although Warburg’s discovery laid the basis of the concept that cancer is 
also a metabolic disease, this idea was contrasted by other scientists of the 
same period and overcome by the tumultuous progress in viral 
carcinogenesis and molecular oncology, leading to the dominant concept of 
cancer as a genetic disease.  
However, tumor cells that metabolize much larger amounts of glucose than 
normal tissue, also exhibit an extremely increased uptake of this carbon 
resource. This phenomenon has been translated in clinical practice and 
positron emission tomography (PET), with the radioactive modified 
hexokinase substrate 18F-2-deoxyglucose (FDG), is routinely used to 
diagnose and monitor tumors [6]. This technique relies on the uptake of 
FDG, which is a transport analogue of glucose, in patient tissues; once 
FDG has entered in cells, it remains trapped by phosphorylation, and it 
does not undergo any further modification. 
 - 7 - 
The molecular bases of the aerobic glycolysis are not clear; although it has 
been proposed that it is a consequence of mitochondrial damage (as 
Warburg himself thought) or an adaptive response to hypoxia, many tumors 
do not present any defect in mitochondria, and no consistent correlation 
between oxygen levels and glycolytic rate has been found yet.  
The benefit for cancer cells of aerobic glycolysis is still a matter of debate, 
but several hypotheses have been proposed over the years. One is that the 
tumor may take advantage of enhanced lactic acid excretion. In fact, the 
high amount of extracellular lactate, derived from pyruvate, may lead to the 
acidification of the tumor microenvironment thus facilitating the disruption of 
tissue extracellular matrix and, hence, promoting cell invasion [7] and 
metastasis. This acidification may also support immune evasion; moreover, 
cell migration is pH dependent and several chemokines and cytokines are 
degraded faster under acid conditions.  
Another fascinating idea is that glucose behaves as an anaplerotic 
substrate. Anaplerosis is defined as the act of replenish tricarboxylic acid 
cycle (TCA cycle) of molecules that have been diverted to biosynthesis. 
Thus, for a cancer cell, a large availability of anaplerotic substrates is a 
prerequisite to couple, under safe conditions, high proliferative activity (and, 
hence, high rates of anabolic reactions, such as protein and fatty acid 
synthesis) with high energetic charge [8].  
Moreover, the high glycolytic rate increases the expression of hexokinase II 
(HXK II), which binds to mitochondria preventing mitochondrial dysfunction 
during cell stress and injury through the interaction with the voltage-
dependent anion channel (VDAC) [9]. It has been shown that, in case of 
mithocondrial dysfunction, VDAC can assume a configuration that 
promotes the release of cytochrome c and, hence, apoptosis. Thus, the 
high HXK II may constitute an advantage in escaping apoptosis.  
Furthermore, an excess of cytosolic ATP production through glycolysis 
inhibits mitochondrial ATP synthase, induces a chemiosmotic backpressure 
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and hyperpolarizes the mitochondrial membrane [8], fixing mitochondria in 
an anti-apoptotic state.  
Additional benefits may derivate from the expression of the isoenzyme 
pyruvate kinase M2 (PK-M2). This low-activity variant allows the diversion 
of glycolytic intermediates into subsidiary pathways such as the 
hexosamine, pentose phosphate, and amino acid biosynthetic pathways, 
thus supporting cellular biomass increase [10]. 
It should be noticed that other nutrients than glucose, including amino acids 
(i.e. glutamine, see below) may also provide energy and carbon moieties 
for macromolecular synthesis, and that the metabolism of many cancer 
cells relies on mutations which are often specific for a particular type of 
tumor. 
 
1.1.1.2 Enzyme mutations and onco-metabolites in cancer 
Many oncogenic mutations affecting both proto-oncogenes, tumor 
suppressor genes or genes for enzymes involved in the intermediate 
metabolism enhance the rates of utilization of anaplerotic substrates. Some 
of these mutations cause the accumulation of the so-called “onco-
metabolites”; the abnormal levels of these compounds cause both 
metabolic and non-metabolic derangements and are often associated with 
the appearance of transformation clues [11].  
For instance, p53 is involved in several aspects of cellular metabolism by 
regulating the levels of a series of genes that affect metabolic pathway 
rates and the abundance of metabolic products. Wild type p53 limits the 
glycolytic flux (see Fig. 2) either directly, by repressing the expression of 
glucose transporter 1 and 4 (GLUT1, GLUT4) [12], or indirectly, through the 
inhibition of NF-κB [13], the repression of the insulin receptor promoter and 
the regulation of phosphoglycerate mutase (PGM) stability. Moreover, p53 
regulates glycolysis though TP53-Induced Glycolysis and Apoptosis 
Regulator (TIGAR), which causes a decline in Fru-2,6-P2 levels, thus 
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inhibiting glycolysis and diverting glucose into the pentose phosphate shunt 
to produce NADPH [13]. Consistently, p53 has been shown to promote 
oxidative phosphorylation (OXPHOS) through mechanisms that include the 
transcriptional activation of cytochrome c oxidase 2 (SCO2) synthesis and 
favouring the use of the TCA cycle for energy production [14]. Furthermore, 
p53 seems to be involved in the regulation of glutaminolysis (see below) 
and fatty acids oxidation (FAO), inducing mitochondrial FAO during glucose 
starvation. 
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Fig. 2 p53 regulates glycolysis (from [14]). 
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Loss-of-function germ-line mutations in genes encoding for Krebs cycle 
enzymes, such as succinate dehydrogenase (SDH) and fumarate 
hydratase (FH), promote oncogenesis behaving as oncosuppressor genes 
in rare forms of enhanced cancer susceptibility.  
In particular, mutations of the SDH (subunits B, C and D) characterize 
familiar paragangliomas and pheochromocytomas, tumors of the 
parasympathetic and sympathetic nervous system [15]. These were the first 
tumor cells to be identified with a defined genetic defect of mitochondrial 
respiration, thus, conforming to Warburg's original hypothesis. SDH 
oxidizes succinate to fumarate (see Fig. 3), contributing to the generation of 
ATP by oxidative phosphorylation. Mutations of SDH lead to the 
accumulation of succinate, resulting in both a serious incapacity in the TCA 
cycle and a limited capacity to utilize respiration (OXPHOS) for ATP 
production [16].  
Mutations of FH are found in familiar form of multiple cutaneous 
leiomyomas, benign smooth muscle tumours of the uterus (uterine 
leiomyomas), and aggressive renal cell carcinomas (HLRCC) of type II 
papillary or collecting duct morphology [17]. FH catalyses the hydration of 
fumarate to malate, which is the following step of SDH in TCA cycle (Fig. 
3). Also for FH, mutations of its gene generate a not-functioning product 
leading to the accumulation of fumarate. 
The accumulation of these onco-metabolites (succinate and fumarate) 
causes the inhibition of the HIF prolyl hydroxylase (PHD), resulting in the 
stabilization of the hypoxia inducible factor (HIF-1α) [18] and, as a 
consequence in the increase of expression of GLUT1 and lactate 
dehydorgenase (LDH) and, hence, of glycolytic rates. Normally, HIF-1α 
hydroxylation by PDH is oxygen dependent, and it is inhibited under 
hypoxic conditions by lack of oxygen. PHD, however, is also dependent on 
α-ketoglutarate (α-KG) levels; in fact, while using molecular oxygen to 
hydroxylate HIF-1α, PHD catalyses the oxidative decarboxylation of α-KG 
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to succinate (Fig. 3) [19]. The activation of HIF-1α by product-inhibition of 
PHD has been termed “pseudo-hypoxia”, and this process can be reversed 
in vitro by the addition of α-KG [16]. 
Another onco-metabolite which causes the pseudo-hypoxia phenomenon, 
is the bio-product of isocitrate dehydrogenase (IDH1/IDH2) mutated 
enzymes. Somatic IDH1/IDH2 mutations occur in some astrocytomas (such 
as oligodendrogliomas), the majority of “secondary” glioblastomas and a 
certain percentage of acute myeloid leukaemias [8]. These isoenzymes 
catalyse the oxidative decarboxylation of isocitrate to α-KG, which is, then, 
available for the further oxidative decarboxylation into succinate operated 
by PHD (Fig. 3). It is unclear if these enzymes should be classified as 
oncogenes or tumor suppressors; however, the oncogenic potential of 
these mutations rely in a new catalytic activity. Mutant IDH, in fact, acquires 
the ability to convert α-KG into (R)-2-hydroxyglutarate (D-2-HG) [20], an 
onco-metabolite that can not be further metabolized. Consistently, gliomas 
with IDH1 mutations show elevated levels of D-2-HG. The production of D-
2-HG lowers the availability of α-KG and, hence, causes the inhibition of 
PHD. However, cells carrying these mutations have also profound changes 
in glutamine, fatty acid, and citrate synthesis pathways. 
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Fig. 3 SDH, FH, and IDH mutations enhanced glycolysis.  
 
Another enzyme frequently mutated in cancer is phosphoglycerate 
dehydrogenase (PHGDH), which is involved in the synthesis of serine and 
glycine (Fig. 4). These two amino acids are relatively abundant in the 
human plasma (more than 100 μM); however, some human cancer cells 
appear to need de novo synthesis of these two amino acids [21]. Both 
serine and glycine are intermediates of several metabolic pathways, which 
support cell survival and growth. Genomic amplification of the PHGDH 
gene, on chromosome 1p12, occurs in more than 15% of the human 
cancers including 40% of melanomas and a limited percentage of breast 
cancer.  
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Moreover, PHGDH is not only important for the synthesis of serine and 
glycine; in fact, it has been demonstrated that cells with high PHGDH 
activity produce large amount of the anaplerotic substrate α-KG (Fig. 4) 
through PSAT1 [22].  
The list of enzymes, whose mutations are associated with transformation, is 
likely expected to elongate. Furthermore it has been proposed that in 
several cancers c-myc controls glutamine metabolism through the induction 
of glutaminase 1 (GLS1), as described in 1.1.2 “Glutamine Addiction”: a 
new concept in cancer metabolism.  
 
 
Fig. 4 Serine and glycine synthesis through PHGDH (from [3]). 
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1.1.1.3 Metabolic alterations as therapeutic targets 
The differences between normal and cancer cell metabolism suggest that 
targeting metabolic dependence could be a useful approach to control 
cancer. Moreover, deregulated metabolism is also linked to drug 
resistance.  
Glycolysis is the main deranged metabolic pathways in most malignant 
phenotypes; thus, it is not surprising that the first approaches to target 
altered metabolism relied on non-metabolizable glucose analogue (see Fig. 
5), such as 2-deoxyglucose (2-DG), 3-bromopyruvate (3-BrPA) and 
lonidamine (LND), which are in pre-clinical or in early-phase clinical trials 
[23]. 
HXK phosphorylates 2-DG glucose analogue into 2-DG-phosphate, a 
compound no more metabolizable. Accumulation of 2-DG inhibits glycolysis 
and ATP production and causes cell cycle arrest and cell death. No single 
trials with 2-DG are ongoing, since alone it does not seem to have 
significant effects on tumor growth; however, it potentiates the effects of 
radiation or chemotherapeutic agent [24]. 3-BrPA inhibits glycolysis 
targeting HXK and depleting cell ATP, which is determinant in some cases 
of drug resistance. For example, in leukaemic cells high ATP levels can 
activate ATP-binding cassette (ABC) transporters, which enhance drug 
efflux leading, hence, to drug resistance. Therefore, 3-BrPA favours drug 
retention and, hence, malignant cell death. Also LND, a derivate of 
indazole-3-carboxylic acid, targets HXK, suppressing glycolysis in cancer 
cells. Moreover it has been demonstrated that LND improved radiotherapy 
of brain tumors. Increased glycolysis is directly associated to glucocorticoid 
resistance, thus inhibition of glycolysis by 2-DG, 3-BrPA or LND increases 
prednisolone-induced toxicity in some cancer models [23].  
Targeting HXK is not the only way to reduce glycolysis. Indeed, since the 
first limiting step of glycolysis is the availability of glucose itself, inhibitors of 
glucose transporters (i.e. WZB117 and ritonavir, which inhibits GLUT1 and 
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GLUT4 respectively) have been also synthesized and are under 
investigation.  
Also the last glycolytic step, the conversion of pyruvate into lactate by LDH, 
has been tested as a therapeutic target; inhibitors of this enzyme produce 
an increase in mitochondrial respiration, a decrease of cellular ability to 
proliferate under hypoxic conditions, and, hence, suppress tumorigenicity 
[25].  
However, it should be noticed that ATP levels negatively regulates 
glycolysis, thus, paradoxically lowering ATP content may enhance 
glycolytic flux, stimulating cancer proliferation. Consistently, some cancers 
express high levels of UnCoupling Protein 2 (UCP2) to suppress ATP 
synthesis and favour glycolysis; in these cases the inhibition of UCP2 may 
yield an approach to reprogram metabolism in cancer cells and to suppress 
tumor cell growth [8].  
Another important tumor suppressor metabolite is dichloroacetate (DCA). 
DCA inhibits pyruvate dehydrogenase kinase (PDK) causing the 
reactivation of pyruvate dehydrogenase (PDH) and, hence, diverting 
glucose from glycolysis to OXPHOS (see Fig. 5). The preclinical trials with 
DCA have shown its effectiveness in a variety of tumors via induction of 
apoptosis [23].  
Besides targeting aerobic glycolysis, it is possible also to slower fatty 
synthesis by inhibiting fatty acids synthase (FASN). FASN expression in 
normal adult tissues is generally very low or undetectable, while it is 
significantly up-regulated in many types of cancer, where it promotes tumor 
growth and survival acting as a metabolic oncogene [26]. Several FASN 
inhibitors have shown antitumor activity including cerulenin, C75, orlistat, 
C93, GSK 837149A and natural plant-derived polyphenols (Fig. 5). 
Also glutamine metabolism has been targeted for metabolic approaches of 
antitumor therapy as described in 1.1.2 “Glutamine Addiction”: a new 
concept in cancer metabolism. As a matter of fact, the first antitumor 
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“metabolic” drug used in clinical practice is L-asparaginase, a bacterial 
enzyme which hydrolyzes asparagine causing massive cancer cell death in 
childhood acute lymphoblastic leukaemia (ALL). This topic is extensively 
discussed below (1.1.3 The first anticancer metabolic drug: L-asparaginase 
(ASNase)).  
Finally, diet may also influence cancer outcome. Ketogenic diet, a low-
carbohydrate, high-fat regimen, mimics the effects of glycolysis inhibitors 
reducing glucose availability, and there are evidences of its antitumor 
effects on gliomas [27]. 
 
 
 
Fig. 5 Targeting tumor metabolism (from [28]) 
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1.1.2 “Glutamine Addiction”: a new concept in cancer 
metabolism 
1.1.2.1 Glutamine is an anaplerotic substrate  
Proliferating cells rely on TCA intermediates to synthesize macromolecules, 
lipids proteins, and nucleic acids. Therefore, TCA role is not only confined 
in ATP production from oxidizable substrates. Consistently, during cell 
proliferation, much of the carbon that enters the TCA cycle is used in 
biosynthetic pathways that consume rather than produce ATP [29]. Thus, a 
continuous leakage of TCA intermediates occurs, a phenomenon known as 
cataplerosis. Conversely anaplerosis, as previously described, is the act of 
replenish TCA intermediates which have been extracted for cataplerotic 
reaction (biosynthesis). Physiologically the balance between anaplerosis 
and cataplerosis depends upon the metabolic state and the specific 
tissue/organ involved. Besides glucose and precursors of propionyl-CoA 
(such as isoleucine, valine and fatty acids), one of the main anaplerotic 
substrate is glutamine. 
Glutamine is the most abundant amino acids in human plasma (0.5-0.8 
mM) and plays an important role in inter-organ nitrogen trafficking from 
muscle to intestine and liver. Mammals are able to synthesize glutamine in 
most tissues, but during periods of rapid growth or illness, the cellular 
demand for glutamine outstrips its supply, and glutamine becomes 
essential. Hence its designation as a “conditionally” essential amino acid. 
Proliferating cells display an intense appetite for glutamine, reflecting its 
incredible versatility as a nutrient and mediator of numerous processes 
[30].  
Glutamine, indeed, is involved in several metabolic processes, which have 
a major impact on cell growth and proliferation, such as cell volume 
regulation, the mTOR –dependent control of protein synthesis (see below), 
and nucleotide synthesis (of both purine and pyrimidines).  
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As far as purine synthesis is concerned, the γ nitrogens of two glutamine 
molecules are added to the growing purine ring, and a third is used in the 
conversion of xanthine monophosphate to guanosine monophosphate. 
Pyrimidine rings, instead, contain one nitrogen from glutamine amido group 
and one from aspartate, and an additional amido nitrogen is added to 
uridine triphosphate to form cytidine triphosphate.  
Moreover, glutamine is involved in the synthesis of other non-essential 
amino acids (i.e. glutamate, asparagine, serine, proline, and alanine) and in 
the redox balance allowing the synthesis of glutathione (GSH).  
GSH is the more abundant intracellular antioxidant and counteracts the 
oxidative stress. This is crucial for the survival of tumor cells, which have to 
endure high levels of oxidative stress due to accelerated metabolism and 
presence of inflammation. GSH is a tripeptide (cysteine-glycine-glutamate) 
and its production is highly dependent on glutamine. In fact, not only 
glutamine metabolism produce glutamate, but the glutamate pool is also 
necessary to get cysteine, the limiting reagent for GSH production. This 
occurs through the Xc− antiporter, which exports glutamate and imports 
cystine. Once taken up, cystine is converted to cysteine inside the cell and 
used in GSH synthesis.  
Moreover, glutamine importance in tumor cell metabolism derives from the 
characteristics it shares with glucose. Both nutrients help to satisfy two 
important needs for proliferating tumor cells: bioenergetics (ATP 
production) and the provision of intermediates for macromolecular 
synthesis [30]. Actually, through the conversion into glutamate, glutamine 
carbon skeleton may replenish both TCA cycle intermediates, acting as an 
anaplerotic substrate, and the intracellular pool of glutamate, since 
glutamine is an abundant extracellular nutrient and glutamate is not (about 
30 μM in plasma of healthy human [31]).  
The conversion of glutamine into glutamate is catalyzed by the phosphate-
dependent glutaminase (GLS), a mitochondrial enzyme highly expressed in 
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tumors and cancer cell lines. There are two types of GLS in mammals, the 
kidney-type (GLS1) and the liver-type (GLS2). 
GLS1 expression is regulated by the oncogene c-myc, which suppresses 
the mircroRNA miR-23a/b that down-regulates the expression of this 
enzyme [32], and correlates with high growth rate and malignancy. 
Conversely, GLS2 is under p53 control [33] in several tissue, and it seems 
to function as tumor suppressor; however, its role appears context specific 
since its enhanced expression contributes to cell survival in some 
neuroblastomas. Once GLS deamidates glutamine to glutamate, the latter 
is, in turn, deaminated to α-KG by the glutamate dehydrogenase (GDH) or 
by transamination (TA) to produce other non-essential amino acids (NEAA). 
Under conditions of glucose shortage, or even under high-glucose 
conditions in a “glutamine addicted” cancer, GDH overbears 
transamination, providing glutamine carbon to TCA and, hence, allowing 
high rates of proliferation. This process, known as glutaminolysis, 
generates reducing equivalents for the electron transport chain and 
OXPHOS, supports macromolecular synthesis, and contributes to cellular 
production of NADPH and lactate (Fig. 6). 
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Fig. 6 Glutaminolysis (from [34]). 
 
These evidences are supported by several observations. First, nuclear 
magnetic resonance (NMR) spectroscopy using 13C-labeled substrates has 
revealed the use of glutamine as the major anaplerotic precursor in 
proliferating glioma cells in both rats and humans [35]. Moreover, glutamine 
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deprivation of fibroblast cultures markedly affected the pool of the TCA 
cycle intermediates fumarate and malate [36]. Thus, since glutamine 
metabolism allows cells to maintain a sufficient anaplerotic flux to balance 
cataplerotic pathways, glutamine shortage may represent a severe 
nutritional stress that may lead to cell cycle arrest and, eventually, to cell 
death.  
 
1.1.2.2 Glutamine is involved in mTOR stimulation 
The highly conserved serine/threonine kinase mammalian target of 
rapamycin (mTOR) is the master regulator of protein synthesis, cell size 
and growth by integrating different signals from nutrients (amino acids), 
growth factors (i.e. insuline-like growth factor), energy status (ATP), and the 
presence of stress conditions.  
mTOR operates through two different complexes mTORC1 and mTORC2, 
which interact with different partner, Raptor (regulatory associated protein 
of TOR) and Rictor (rapamycin-insensitive companion of TOR), 
respectively.  
While mTORC2 controls cell survival by activating AGC kinases and AKT 
[37], mTORC1 regulates the translational machinery mainly through the 
activation of S6 kinase (S6K1) and the inhibition of eIF-4E binding protein 1 
(4E-BP1) [38].  
The activation of S6K1 and the consequent phosphorylation of the 40S 
ribosomal protein S6 drive the translation of 5’ terminal oligopyrimidine tract 
(TOP) RNAs. By controlling 5’ TOP mRNA translation, mTOR upregulates 
the translational machinery under favourable growth conditions [38]. The 
phosphorylation of S6K1 is potently inhibited by rapamycin (especially at 
T389 residue, which is one of the upstream sites in the phosphorylation 
hierarchy). 4E-BP1 is a translation inhibitor; once phosphorylated, it 
dissociates from eIF-4E, the translation initiation factor that allows cap-
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dependent translation. Also 4E-BP1 is blocked by rapamycin. Both S6K1 
and 4E-BP1 phosphorylation are dependant on growth factor availability.  
The binding of growth factors to their specific receptors results in the 
phosphorylation and, hence, the inhibition of tuberous sclerosis complex 2 
(TSC2), which, in complex with TSC1, has GTPase-activating protein 
(GAP) activity and stimulates the transition of the GTPase Rheb from its 
active (GTP-bound) to inactive (GDP-bound) state. The activation of Rheb 
is indispensable for mTOR activation in response of all stimuli [39]. The 
increasing Rheb-GTP and Rheb-GDP ratio, caused by the inhibition of 
TSC2 by growth factors, drives mTOR stimulation.  
In order to balance anabolic and catabolic processes, single cells and 
multicellular organisms need to tightly coordinate their usage of energy as 
well as amino acids. It is not surprising that amino acids availability 
carefully regulates the phosphorylation of S6K1 and 4E-BP1. However, 
unlike the growth factor signalling, the precise mechanism by which amino 
acids powerfully stimulate mTORC1 is not completely understood.  
It has been suggested that amino acids regulate the kinase in a TSC-
independent way, since amino acid deprivation suppresses mTORC1 
signalling even in TSC2-/- cells where mTORC1 is hyper-activated [40]. 
Consistently, it has been demonstrated that Rag GTPases (RagA, RagB, 
RagC and RagD) are crucial in transmitting amino acids content. The 
presence of amino acids favours the transition of the heterodimer 
RagA/RagB from GDP bound to GTP bound and of the heterodimer 
RagC/RagD from GTP bound to GDP, and, hence, sustains mTOR activity 
[41].  
It has been proposed that in amino acids plenty cells, the system 
constituted by the lysosomal v-ATPase and the Regulator complex, is 
activated through a lysosomal ‘inside-out’ mechanism and promotes the 
GTP charging of RagA/B, which in turn recruits mTOR to the lysosome 
surface where it is activated by the lysosome-associated Rheb (see Fig. 7) 
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[42]. Consistently in amino acids starved cells mTORC1 has a cytoplasmic 
localization.  
 
  
 
Fig. 7 Nutrient signalling to mTOR (from [39]). 
  
More recently, Sabatini laboratory has identified an octomeric complex, 
named GATOR, which is a critical regulator of the pathway that signals 
amino acids sufficiency to mTOR [43]. The GATOR1 sub-complex has GAP 
activity for RagA and RagB and its loss makes mTORC1 signalling 
insensitive to amino acid deprivation. 
It is known that not all the amino acids are required for mTORC1 activation. 
In particular, leucine is one of the most powerful activators. It has been 
suggested that leucine content is sensed by another mechanism, different 
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from that described above. According to this theory, leucine availability is 
sensed by the leucyl-tRNA synthetase (LRS), which is the enzyme that 
charges leucine to its tRNA allowing protein synthesis. In mammals, LRS 
acts as a GAP for RagD, but not RagC, and stimulates the formation of the 
GDP-bound form of RagD, thereby promoting configuration of the active 
Rag heterodimer complex [44].  
These findings suggest that mTORC1 activation via amino acid sensing 
may occur at various cellular localizations and by different mechanisms. 
Thus, it can not be excluded that different amino acids may contribute to 
mTORC1 activation through different pathways. Glutamine has also been 
repeatedly involved in mTORC1 stimulation, although its role is more 
controversial.  
Nicklin et al. proposed that glutamine indirectly activates mTOR kinase by 
promoting leucine uptake through a tertiary active transport [45]. However, 
it has been demonstrated that glutaminolysis is necessary for GTP loading 
of RagB and, hence, for the activation of mTOR [46]. According to this 
theory, glutaminolysis may have a dual role in cancer cells, sustaining the 
TCA cycle and activating mTORC1, thus maximizing protein synthesis. 
On the other hand, mTORC1 is able to promote glutamine-dependent 
anaplerosis by activating GDH, through the transcriptional repression of the 
GDH inhibitor sirtuin 4 [47]. Moreover, the activity of the Na+-dependent 
system A transporter (SNAT2), which mediates concentrative glutamine 
transport, has been linked to mTORC1 regulation [48]. These findings 
strengthen the links between glutamine and mTOR activation.  
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1.1.2.3 Targeting glutamine metabolism 
Some malignancies rely on glutamine to fulfil TCA cycle, the so-called 
“glutamine addicted” tumors. Thus, targeting glutaminolysis may provide a 
useful tool for the control of these cancers.  
For instance, it has been demonstrated that Bis-2-[5-phenylacetamido-
1,2,4-thiadiazol-2-yl] ethyl sulfide (BPTES), an inhibitor of GLS (Fig. 6), 
slows the growth of glioblastoma cells with an isocitrate dehydrogenase 1 
(IDH1) mutation, a cell model where glutamine use is enhanced [49]. As a 
consequence of BPTES treatment a decrease in glutamate and α-KG levels 
and an increase of glycolytic intermediates occur.  
GLS may also be inhibited through 968, a compound that targets a specific 
carboxyl-terminal splice variant form of GLS1 (Fig. 6). 968 blocks the 
growth of human breast cancer and B lymphoma cells without affecting 
normal cells [50]. 
Moreover, three glutamine analogues, acivicin, 6-diazo-5-oxo-L-norleucine 
(L-DON) and azaserine (see Fig. 6), were demonstrated many years ago to 
have a significant cytotoxic activity in vitro but attempts to translate these 
effects in vivo were hampered by significant multi-organ toxicity [8], such as 
gastrointestinal alterations, myelosuppression, and neurotoxicity.  
Furthermore, it has been demonstrated that glutaminolysis activates mTOR 
and, indeed, the inhibition of GLS with BPTES or DON prevents mTOR 
activation [46]. Thus, targeting glutaminolysis or GLS may sensitize cancer 
cells to common chemotherapeutic agents by reducing mTORC1 activity.  
It is also possible to target the flux form glutamate to α-KG. For example, 
aminooxyacetate (AOA) inhibits aminotransferases and has demonstrated 
efficacy in breast adenocarcinoma xenografts and neuroblastomas in mice. 
Moreover epigallocatechin gallate (EGCG), a green tea polyphenol, inhibits 
GDH, and it has been used to kill glutamine-addicted cancers [34].  
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Since glutamine is a pleiotropic substrate, useful for several metabolic 
reactions, including mTOR activation, glutamine deprivation should be 
more efficient in killing cells than glutaminolysis inhibition.  
On the basis of this assumption, it has been recently demonstrated that 
inhibiting glutamine uptake, via the knockdown of the Na+-dependent 
neutral amino acid transporter ASCT2, induces apoptosis and inhibits 
tumor formation in a acute myeloid leukaemia (AML) xenotransplantation 
model [51]. Consistently the inhibition of ASCT2 through γ-L-glutamyl-p-
nitroanilide (GPNA) limits lung cancer cell growth. Moreover, suppressing 
glutamine uptake with GPNA stimulates the uptake of 3-BrPA [34].  
The antileukemic drug L-asparaginase has the ability to hydrolyze both 
asparagine and glutamine, causing a severe, although transient, glutamine 
depletion in vivo (see1.1.3 The first anticancer metabolic drug: L-
asparaginase (ASNase)). Thus, the use of L-asparaginase is likely to be 
extended from ALL, where it still represents one of the first line drugs, to 
other haematological and non-haematological malignancies. It should be 
noticed that glutamine shortage stabilizes Glutamine Synthetase (GS), the 
enzyme that catalyzes glutamine synthesis from glutamate and ammonium. 
GS expression, in fact, is regulated in both a transcriptional and post 
transcriptional way [52, 53] and may cause resistance to glutamine-
depleting treatments such as L-asparaginase. However, irreversible 
inhibitors of GS are available, such as methionine-L-sulfoximine (MSO) or 
phosphinothricin (PPT). These compounds have an amino acidic structure 
(Fig. 8) and mimic the phosphorylated intermediate of GS-mediated 
reaction, thus avidly binding the catalytic site of the enzyme. Furthermore, 
in asparaginase resistant models MSO powerfully synergizes ASNase 
cytotoxic effects [54, 55].  
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Fig. 8 Structures of MSO and PPT 
 
An alternative agent that deplete plasma glutamine is phenylbutyrate, an 
FDA-approved drug for the treatment of hyperammonemia in patients with 
acute liver failure or with congenital urea cycle disorders [56]. In humans, 
phenylbutyrate spontaneously breaks down to form phenylacetate, which is 
conjugated with glutamine by an hepatic enzyme into 
phenylacetylglutamine which is then excreted by urine [56].  
 
1.1.3 The first anticancer metabolic drug: L-asparaginase 
(ASNase)  
1.1.3.1 ASNase mechanism of action 
The enzyme L-asparaginase (L-asparagine amidohydrolase, EC: 3.5.1.1, 
ASNase), has been the cornerstone of acute lymphoblastic leukaemia 
(ALL) therapy since 1970.  
The antineoplastic properties of this enzyme were discovered in 1961 by 
Broome, who isolated ASNase from guinea pig serum and ascribed to its 
presence the anti-lymphoma effects of guinea pig serum described some 
years before [57]. Afterwards, ASNase has been isolated from several 
types of bacteria, mainly from Escherichia coli and Erwinia chrysanthemi, 
notably because of their use in the clinic.  
The antileukemic effects of ASNase are related to its ability to catalyze the 
hydrolysis of asparagine into aspartic acid and ammonium. Asparagine is 
not essential for normal cells, but it becomes essential for leukemic blasts, 
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which cannot synthesize asparagine de novo [58] due to the low expression 
of asparagine synthetase (ASNS). However, the enzymes used in clinic are 
also endowed, with lower affinity, with a glutaminolytic activity, given that 
they hydrolyze glutamine into glutamic acid and ammonium (Fig. 9).  
Although it is believed that several side effects of ASNase are attributable 
to glutamine depletion, it is also demonstrated that deamination of 
glutamine correlates with enhanced serum asparagine deamination in vivo 
[58], thus enhancing antileukemic effects of the drug. 
 
Fig. 9 ASNase deaminates both asparagine and glutamine (from [59]). 
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Nowadays, three different ASNase preparations are available in clinical 
practice: the native E. coli (Colaspase), the pegylated E. coli asparaginase 
(Pegaspargase), and the native E. chrysanthemi (Crisantaspase or 
Erwinase).  
Pegaspargase is the most used product available in the United States [60], 
because of its efficacy and low rate of allergic reactions. On the other hand, 
Crisantaspase has a 10-fold higher glutaminase activity than Colaspase, 
with favourable Km and faster kcat [61].  
ASNases work as tetramers (133-141kDa) with four active sites, each 
constituted by the N-terminal domain of a given subunit and the C-terminal 
domain of another subunit [62].  
ASNases are administered either by intramuscular or intravenous injections 
and maintain optimal enzymatic activity at 0.4-0.7 U/ml. In antibody-
negative patients, asparagine is depleted from 50 μM to 3 μM or lower, 
while glutamine from 600 μM to less then 80 μM.  
In vivo studies, revealed that the half-life of Crisantaspase and Colaspase 
are similar [63], while Pegaspargase has an higher stability, allowing 
reduction in administration frequency (every two weeks instead of every 2-5 
days).  
After administration, it is known that ASNase is mainly confined in the 
vascular space, although it has been detected in the pleural fluid and 
ascites, but not in the cerebrospinal fluid, even when used at high dosage. 
There are several opinions on ASNase clearance. Since it is not detected in 
the urine it has been suggested that it is eliminated by the 
reticuloendothelial system, otherwise it could be clived by proteolytic 
enzymes (i.e. cathepsin) [63].  
Currently, ASNases are only used in the therapy of ALL and, more recently, 
of nasal-type NK lymphoma. However, there are several attempts to extend 
ASNase indications to other lymphomas of T-cell lineage and selected 
subtypes of AML. Moreover, ASNase therapeutic uses could be extended 
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to non-hematologic malignancies, for example ovarian cancers [64] and, 
possibly, other solid tumors with low ASNS expression. It has been recently 
proposed that local ASNase delivery would kill glutamine auxotrophic 
tumors [65]. 
 
1.1.3.2 Mechanism of resistance to ASNase 
Considering the bacterial origin and the large molecular weight of ASNase 
it is not surprising that one of the mechanisms of drug resistance relies on 
antibody production against the exogenous enzyme.  
The production of antibodies causes an accelerated clearance of ASNase 
that must be by-passed changing the type of enzyme used, commonly from 
the E. coli native product to the non-cross reactive E. chrysantemi 
asparaginase. In fact the immunogenic epitopes of Colaspase and 
Crisantaspase are different and frequently correspond to the flexible loops 
on the protein surface [62]. However, it is not uncommon that patients with 
clinical allergy to E. coli ASNase develop antibodies against Erwinase (7-
20%).  
Another factor that may causes ASNase resistance is the up-regulation of 
ASNS in the leukemic blast [62]. Transcription of ASNS increases in 
response to amino acid deprivation, a condition that activates the amino 
acid response (AAR). The AAR is composed of several transduction 
pathways that terminate in the induction of genes encoding for proteins 
involved in metabolic rescue or, if the stress is not relieved, apoptosis. In 
the absence of asparagine, uncharged tRNA activates general control non 
repressed 2 (GCN2), a serine/threonine kinase which phosphorylates 
eukaryotic initiation translation factor 2α (eIF2α). The phosphorylation of 
eIF2α triggers a pleiotropic response that leads to the attenuation of protein 
synthesis and to the expression of transcription factors such as ATF4, 
followed by the increased transcription of ASNS. 
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Under these conditions, ASNase from E. chrysanthemi appears endowed 
with a significant advantage, due to its higher glutaminase moiety. Indeed, 
the synthesis of asparagine is strictly dependent on glutamine availability, 
since ASNS converts aspartate into asparagine, using the amido group of 
glutamine. Hence, glutamine shortage inhibits asparagine synthesis. 
A few years ago, Iawamoto et al. proposed that resistance to ASNase may 
depend on a trophic relationship between bone-marrow mesenchymal stem 
cells (MSC) and leukemic blasts [66]. Confined niches in the bone-marrow 
microenvironment are a crucial place of interaction between MSC and 
haematopoietic stem cells (HSC), and it has been demonstrated that MSC 
could support cancer cell growth through several mechanisms [67]. In the 
work of Iawamoto, it has been demonstrated that MSC have a large 
amount of ASNS and, hence, can produce asparagine protecting ALL 
blasts from ASNase treatment in vitro (see the model in Fig. 10). 
Consistently, in the bone-marrow aspirates obtained during ASNase 
treatment an increase in aspartic acid content occurs [68, 69], probably due 
to a release of asparagine, which is rapidly cleaved by ASNase.  
Moreover, ASNase resistance could be also supported by the release of 
glutamine: indeed, adipocyte-differentiated 3T3-L1 cells secrete glutamine 
reducing ALL blast sensitivity to ASNase [70].  
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Fig. 10 Model of ASNase drug resistance (from [71]) 
 
1.1.3.3 ASNase toxicity 
Toxicity of ASNase is mainly related to immunological sensitization, with 
hypersensitivity reactions against the exogenous protein, and to the 
adverse event related to inhibition of protein synthesis.  
The allergic reactions are the most common toxic effects and are caused 
by antibodies against ASNase in circulation; they mainly consist of urticarial 
but symptoms of hypersensitivity may range from localized erythema to 
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systemic anaphylaxis [63]. Moreover, tissues with high rate of protein 
synthesis, such as liver and pancreas, are affected by amino acid shortage 
caused by ASNase.  
Liver disorders are common, in particular hepatotoxicity characterized by 
fatty acid accumulation, increase of transaminase and bilirubin levels and 
decrease in serum albumin, fibrinogen and lipoprotein levels. Moreover, 
reduced protein synthesis in the liver causes also endocrine disorders, 
thyroxine-binding globulin (TBG), the major thyroid hormone transport 
protein, and sex-hormone-binding globulin (SHBG), the glycoprotein that 
binds androgens and estrogens, are transiently, but markedly, decreased 
upon ASNase administration [72, 73]. However, hepatic functions usually 
return to normal when drug is cleared or discontinued.  
Coagulation dysfunction, with decreasing levels of clotting factors, 
antithrombin III, plasminogen, and protein C and S [63], are frequently 
associated with ASNAse treatment. Bleeding or thrombotic complications 
are therefore reported with some frequency, while neutropenia and 
thrombocytopenia are rare. 
10-16% of patients develop pancreatitis characterized by elevation of 
serum amylase and lipase, and associated with abdominal and/or back 
pain, anorexia, nausea and vomiting [74]. Some patients develop signs and 
symptoms of diabetes due to damage of islet cells, and subsequent 
decrease in the synthesis of insulin.  
Nervous system disorders, like lethargy, somnolence, dizziness, confusion, 
may also occur. Neurotoxicity may be caused by glutamine deficiency or by 
increased blood ammonia levels, even if a correlation between ammonia 
levels and degree of toxicity has not been established [63].  
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1.2 Targeting glutamine in “glutamine addicted” 
cancers 
As described before (see 1.1.2 “Glutamine Addiction”: a new concept in 
cancer metabolism), glutamine withdrawal may produce a synthetic lethality 
in those tumors which preferentially use this amino acid to fulfil their 
anaplerotic demands. Although it has been proposed that c-myc 
hyperexpression, by enhancing glutaminolysis, is a marker of “glutamine 
addiction”, it is also true that metabolic profiles of tumors depend on the 
tissue in which cancer arises [75]. Thus, markers of glutamine dependence 
are still unknown. GS, encoded by the gene GLUL, is the only enzyme able 
to catalyse glutamine synthesis and has been considered a factor of 
glutamine-depletion resistance. GS is not expressed ubiquitously, but it is 
abundant in skeletal muscle, perivenous hepatocytes, astroglial cells and 
other organs.  
 
1.2.1 GS-positive HepatoCellular Carcinoma (HCC) 
1.2.1.1 Epidemiology of HCC 
Hepatocellular carcinoma (HCC) is the most common type of malignant 
liver tumor and the third leading cause of cancer death worldwide [76]. 
HCC is the fifth most common cancer in man and the seventh in woman, 
and most of the burden (85%) is in developing countries, especially in those 
regions where infection of hepatitis B virus (HBV) is endemic (South Asia, 
Sub-Saharan Africa). However the incidence is steadily rising across most 
of the developed world due to the use of alcohol, the rise of obesity, 
infection of hepatitis C virus (HCV), and increasing age. HCC rarely occurs 
before the age of 40 years with an overall sex ratio man : female of 2.4 [77]. 
Many aetiological factors of HCC are well known: HBV or HCV infection, 
aflatoxin exposure, alcohol abuse, obesity. The distribution of these risk 
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factors among patients with HCC is highly variable, depending on the 
geographic region and the ethnic group. These agents promote chronic 
hepatitis and cirrhosis, favouring the formation of dysplastic nodules, 
defined as pre-neoplastic lesions. More rarely, HCC occurs in a healthy 
liver, and it is often due to a malignant transformation of a hepatocellular 
adenoma [78].  
HBV and HCV infection are presents in 70-80% of the causes of HCC. HBV 
is a small enveloped DNA virus, member of the Hepdanaviridae family, and 
integrates its DNA into the host genome [79]. Although the mechanisms 
underlying transformation may be complex, it is known that viral DNA 
integration disrupts the functioning of several genes favoring 
transformation. HBV is the leading risk factor for HCC globally and is 
thought to account for at least 50% of the cases of HCC. On the other 
hand, HCV infection incidence depends on geographical region and it is 
found in 70-80% of HCC patients in Japan, 40-50% in Italy and Spain, 
about 20% in the United States [80]. HCV is an RNA virus, member of 
Flaviviridae virus, unable to integrate into the host genome. It is thought 
that HCV increases the risk of HCC by promoting inflammation and fibrosis 
of the infected liver that, eventually, results in liver cirrhosis.  
Aflatoxins are food-borne secondary fungal metabolites that are 
hepatotoxic, hepatocarcinogenic, and mutagenic. Aflatoxins are produced 
mainly by Aspergillus flavus and A. parasiticus, which commonly 
contaminate foods such as peanuts, grain, legumes, and corn [81]. 
The most potent carcinogen among aflatoxins is the aflatoxin B1 (AFB1). 
AFB1 is metabolized by cytochrome P450 into a reactive epoxide, able to 
form a covalent bond with guanine. The resulting adducts can promote 
cellular and macromolecular damage, including the GC → TA transversion 
mutation at the third position of codon 249 of the p53 gene [82].  
The risk of HCC significantly increases with an exposure of > 80 g ethanol 
per day, and was elevated 54-fold in the presence of both viral infection 
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and alcohol exposure. However, no molecular evidence of alcohol-induced 
carcinogenesis has been already defined. Alcohol per se is not cytotoxic, 
but its metabolism is a powerful source of cell damage. Ethanol, indeed, is 
metabolized by alcohol dehydrogenase, catalase and cytochrome P4502E1 
(CYP2E1). All these reactions lead to the highly reactive, protein synthesis 
inhibitor acetaldehyde; additionally, CYP2E1 reaction leads to the formation 
of reactive oxygen species (ROS) and, hence, to DNA, protein and 
membrane damage [83]. 
More recently, it has been proposed that another cause of HCC is obesity. 
Fatty enriched, hyper-caloric diets can alter hepatic metabolism and 
promote inflammation leading to non-alcoholic fatty liver disease (NAFLD) 
or, even worse, to the more severe non-alcoholic steatohepatitis (NASH). 
NASH is characterized by prominent steatosis and inflammation, and 
enhances HCC incidence [84]. 
 
1.2.1.2 Therapy of HCC 
The poor prognosis of HCC is often due to late diagnosis. Thus, screening 
and surveillance are highly important for the early detection of HCC 
especially in patients considered to be at high risk (i.e. patients with 
cirrhosis or HBV infection). This screening is based on ultrasounds and α-
fetoprotein (AFP) dosage.  
The treatment of HCC is particularly challenging because of patient-
associated variables and the high resistance to classical 
chemotherapeutics, such as cisplatin and doxorubicin, to hormone therapy, 
or to immunotherapy. Currently, HCC therapeutic approaches are based on 
liver transplant, surgical resection, embolization, thermal ablation, and 
biological therapies. 
Liver transplant is considered the most effective method to treat both 
cancer and liver disease, from which cancer arise. Patients receiving a 
transplant have a 4-year overall survival of 75% and only an 8% risk of 
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recurrence [85]. However the limited availability of donor reduces the 
efficacy of this approach.  
Surgical resection remains the golden standard for patients with early-stage 
HCC, whose hepatic functions have not yet been impaired. However, the 
recurrence rate after resection is approximately 50% at 2 years and 75% at 
5 years [86].  
Transarterial chemoembolization (TACE) involves the intra-arterial injection 
of a cytotoxic agent (doxorubicin, cisplatin, or mitomycin), with or without 
lipiodol, plus an embolic agent into the hepatic artery that supplies the 
tumor. This technique is used in patients who can not undergo surgery for 
the extent or the distribution of the neoplasia. However, the efficacy of this 
approach is limited, with a long-term outcome of only 30% overall survival 
[87]. Conventional TACE has been improved by developing a new drug 
delivery system: the doxorubicin-eluting beads (DEBs). DEBs are 
preformed deformable microspheres loaded with up to 150 mg of 
doxorubicin. Encouraging results, with 1-year and 3-year survival rates of 
89.9% and 66.3% respectively, have been reported [86]. 
One of the most used approaches is thermal ablation (radio-frequency, 
microwaves, laser-induced interstitial thermotherapy, high-intensity focused 
ultrasound, cryoablation). Another kind of ablation used is the chemical 
ablation with ethanol or acetic acid. These methods cause necrosis inside 
and around the tumor. In general they are preferentially used in the 
presence of small lesions (< 3 cm), since the long-term efficacy of these 
techniques drops with increasing size and numbers of lesions [88]. 
Recently, it has been approved a biological therapy for HCC based on a 
multikinase inhibitor, sorafenib. This drug inhibits tyrosine-kinase receptor 
(VEGF-R2 and PDGF-R-β) and several intracellular serine/threonine-
kinases involved in cell proliferation and angiogenesis. Although sorafenib 
represents the major advancement in the management of unresectable 
advanced-stage HCC, the clinical benefit appears to be modest and short-
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lived, even in patients with preserved liver function. In addition, there is 
currently no reliable predictive biomarker for indicating susceptibility to 
treatment [87]. 
 
1.2.1.3 Carcinogenesis of HCC 
It is known that HCC carcinogenesis is a multi-step process. After liver 
injury a continuous cycle of destructive–regenerative process begins and 
promotes chronic liver disease. This condition fosters liver cirrhosis 
culminating in malignant transformation (Fig. 11). 
  
 
Fig. 11 Histopathological progression of HCC, from [89]. 
 
During this process, genetic and epigenetic alterations occur and result in 
the altered expression of cancer-related genes such as oncogenes and 
tumour-suppressor genes (Fig. 12) including TP53, Rb and p16, PTEN, c-
MYC, β-catenin, ErbB receptor family members, MET and its ligand 
hepatocyte growth factor (HGF), E-cadherin and cyclooxygenase 2 
(COX2). 
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Fig. 12 Gene alteration in HCC, from [90]. 
 
p53 arrests cell cycle after DNA damage, promotes DNA repair, and 
triggers apoptosis. It is the most extensively studied gene in solid tumors 
and its mutations are present in at least 30% of HCC. It seems plausible 
that p53 mutations might operate in either early or late stages of HCC 
development, depending on the context [89]. 
The retinoblastoma (Rb) gene negatively regulates cell cycle through the 
binding of the transcription factor E2F. The p16 gene, also known as cyclin-
dependent kinase inhibitor 2A gene, is the regulator of the Rb pathway. 
Inactivation of either Rb or p16 is frequently found in HCC (81%) [90]. 
Phosphatase and tensin homolog (PTEN) is involved in cell survival 
regulating the phosphoinositide-3-kinase/Akt signalling pathway. At least 
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40% of HCC poorly express PTEN, a phenomenon attributable to the 
increased expression of miR-21 [91]. 
Myc is a potent proto-oncogene which codes for a protein involved in 
mediating the cellular response to growth factors. It has been reported a 
correlation between myc expression and HCC tumor size [92].  
The ErbB family of receptor tyrosine kinases consists of four members 
(ERBB1–ERBB4), which have been implicated in the development of 
various types of human cancers. ERBB1, known as epidermal growth factor 
receptor (EGFR), and ERBB2 have been found over-expressed in 68% and 
84% of HCC cases, respectively and correlated with a more aggressive 
phenotype, such as a high proliferation index, intrahepatic metastasis, de-
differentiation and large tumour size [89]. 
Aberrant DNA methylation patterns have been reported in human HCC; 
moreover specific hypermethylation events targets p16, E-cadherin, and 
COX2. In fact, HCC cells treated with de-methylating agents increases p16 
and COX2 expression, and this increase is associated with the inhibition of 
cell proliferation. 
Re-activation of developmental pathways, such as the Wnt/β-catenin signal 
(see below), Notch (see below) and Hedgehog (Hh), often occurs in HCC.  
Hh pathway is an evolutionarily conserved signaling mechanism that 
controls many aspects of cell differentiation and the development of tissues 
and organs during embryogenesis, promoting cell growth and inhibiting 
apoptosis. Significant hyper activation of Hh signaling has been observed in 
liver injury and cirrhosis and plays an important role in the progression of 
HCC, where an increase of Hh related molecules has been reported [93]. 
Lastly, the re-activation of telomerase, correlating with increased 
telomerase reverse transcriptase (TERT) mRNA levels, arises in nearly 
90% of human HCC. Telomerase re-activation may promote HCC 
progression and recurrence after resection [94]. 
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1.2.1.3.1 Wnt/β-catenin hyper-activation in HCC 
Since its discovery in 1982, the Wnt pathways have been associated with 
cell proliferation and cancer, as they trigger G1 phase progression through 
Cyclin D1 expression and c-Myc transcriptional inductions [95]. In 1998, the 
link between Wnt signaling and the liver was initially established through 
the demonstration that β-catenin activating mutations occur in 20 to 40% of 
HCC. Moreover, β-catenin mutations characterize at least 70% of 
hepatoblastomas (HB), the most frequent malignant paediatric liver tumor. 
Thus, β-catenin is the most frequently altered oncogene in liver cancers.  
Wnt signalling has a prominent role in stem cell biology, including self-
renewal, pluripotency, and differentiation of both embryonic and adult stem 
cells. Moreover, it is crucial for the development of liver by regulating 
hepatoblast proliferation, survival and differentiation. In adult liver β-catenin 
is mainly a cytoskeletal protein, localized mostly at the hepatocyte 
membrane, which connects E-cadherin with F-actin.  
In the absence of Wnt ligand, free β-catenin is rapidly bound in a complex 
with Axin, adenomatous polyposis coli (APC), casein kinase 1 (CK1) and 
glycogen synthase kinase 3β (GSK3β), which collectively constitute the 
destruction complex. β-catenin is phosphorylated by CK1 and GSK-3β at 
specific serine/threonine residues located at the N-terminal region of the 
protein, a reaction facilitated by the scaffolding proteins Axin and APC [96]. 
Once phosphorylated β-catenin is ubiquitinated and eventually destroyed 
by the proteasome (Fig 13).  
The binding of Wnt lingands with the seven-pass transmembrane Frizzled 
(Fz) receptors on the surface of cells induces the association with the low-
density lipoprotein receptor related protein (LRP) 5/6. This co-receptor 
complex triggers activation of the canonical Wnt pathway. Dishevelled (Dvl) 
is recruited to the Fz receptor and the Fz/Dvl complex, in turn, relocates 
Axin to LRP5/6. Then, Axin-bound GSK-3β and CK1 phosphorylate 
LRP5/6, leading to the inactivation of GSK-3β.  
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The hypophosphorylated form of β-catenin is more stable and it is 
accumulated in the cytoplasm. Although β-catenin lacks a nuclear 
localization sequence, it then translocates to the nucleus through an 
unknown mechanism which may involve an interaction with both 
components of the nuclear pore complex and lymphoid enhancer factor or 
T-cell factor (LEF/TCF), its nuclear binding partners. Once in the nucleus, 
β-catenin binds to LEF/TCF (Fig 13), displacing the transcriptional inhibitor 
Groucho, and, in complex with TCF, initiates transcription of target genes 
[97], such as c-Myc, Cyclin D1, VEGF, and GS.  
 
 
Fig 13 Wnt pathways off state (a) and on state (b), from [98].  
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In normal adult liver, this pathway is important for imparting zonation [99]. 
In fact, pericentral (PC) hepatocytes express cytoplasmic and nuclear β-
catenin in addition to membranous localization (Fig. 14). Here, β-catenin 
regulates the expression of genes that encode for enzymes critical in 
ammonia and xenobiotic metabolism (GS, glutamate transporter-1 (Glt1), 
and cytochrome P450 family members). Conversely, the hepatocytes in the 
periportal (PV) zone show higher APC protein expression and, as a 
consequence, less dephosphorylated β-catenin. 
 
 
Fig. 14 Liver zonation. PV = portal vein, CV = central vein, from [95].  
 
Moreover β-catenin is essential for maintaining adherens junctions through 
the E-cadherin binding. This binding is controlled by the phosphorylation of 
β-catenin at a specific tyrosine residue (Y654). The disruption of adherens 
junctions causes an impairment in the apical trafficking of specific proteins 
and results in many morphogenetic processes that contribute to motility and 
metastasis in the presence of aberrant growth [100]. 
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Another important function of β-catenin is the contribution to liver 
regeneration. Adult liver, in fact, has the unique capacity to regenerate after 
insult and loss of most of its mass. During liver regeneration, i.e. after 
partial hepatectomy, β-catenin accumulates and translocates into the 
nucleus. This mechanism is due to a decrease in serine phosphorylation 
and a subsequent decrease in protein degradation, and not a result of 
changes in gene expression [97]. As a consequence, an increase in cyclin-
D1 and c-myc expression is observed after partial hepatectomy, confirming 
the positive impact on cellular proliferation of β-catenin. Furthermore β-
catenin is also one of the downstream effectors of hepatocyte growth 
factor, which itself is a significant player in the process of liver regeneration 
[101]. 
Considering the importance of Wnt/β-catenin in the liver homeostasis, it is 
not surprising that the hyper-activation of this pathway contributes to the 
development of a malignant phenotype, although it is not sufficient for 
initiation and progression of HCC.  
The dys-regulation of this pathway may be caused by mutation (i.e. point 
mutation or deletion) affecting the exon 3 of CTNNB1, the gene encoding 
for β-catenin itself (about 12-26% of HCC) or the AXIN1 and AXIN2 genes 
(8-13%) [102]. In both cases, the affinity of β-catenin for the degradation 
complex is lowered, and β-catenin results hypophosphorylated, 
accumulates in the cytoplasm and, hence, in the nucleus. The activation of 
this pathway leads to the increased expression of a number of target genes 
among which a preeminent position is held by GLUL, the gene encoding for 
GS.  
The relationship between β-catenin activation and GLUL expression is so 
strong that GS positivity in immunocytochemistry is considered a bona fide 
indicator for β-catenin pathway activation in human HCC [103].  
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1.2.1.3.2 Notch signalling in HCC 
The Notch signalling is a highly conserved system and plays an important 
role in stem cell self-renewal and differentiation.  
This pathway is constituted of four different notch receptors (Notch1, 
Notch2, Notch3, and Notch4). Each receptor is a single-pass 
transmembrane protein, with a large extracellular portion and a small 
intracellular region. Maturation of Notch receptor consists in the synthesis 
as a single transmembrane polypeptide and in post-translational 
rearrangements. These modifications, such as glycosylation and cleavage, 
occur during translocation to the cell surface through the trans-Golgi 
system (see Fig. 15).  
Neighboring cells send signals through five ligands, belonging to two 
different groups. The first group includes Jagged1–2, the second group 
Delta-like -1, -3 and -4 (DLL-1, -3, -4) [104]. The receptor is normally 
triggered via direct cell-to-cell contact, in which the transmembrane proteins 
of the cells in direct contact form the complex between ligands and Notch 
receptors. Ligand binding promotes a conformational change which allows 
two proteolytic processing events mediated by an ADAM/TACE 
metalloprotease acting outside the cell, and the γ-Secretase, which 
operates at the cytoplasmic side [105]. As a result of proteolysis, the Notch 
intracellular portion (ICN) is released and is able to translocate into the 
nucleus. Once in the nucleus, ICN displaces the transcriptional repressor 
complex CSL and recruits co-activators, such as PCAF, GCN5, p300, and 
MAML1, thereby activating the transcription of several downstream target 
genes. Among direct or indirect Notch effectors, several are involved in 
proliferation, including c-myc, p21, p27, Cyclin D1 [104] (Fig. 15). 
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Fig. 15 Notch pathway, from [106]. 
 
Notch activation has been described in different kinds of cancer (i.e. 
leukaemia or solid tumor as prostate and breast cancer [107, 108]), 
although in other case it has been considered as tumor suppressor [109]. In 
fact, other signalling pathways influence whether Notch functions as a 
tumor suppressor or oncogene in a particular tissue.  
In the liver, Notch acts in a temporal- and dose-dependent manner to 
coordinate biliary fate and morphogenesis [110]. It has been proposed that 
Notch1 over-expression inhibits HCC progression by promoting cell cycle 
arrest and apoptosis [111, 112]. Conversely, there are growing evidences 
of the oncogenic role of Notch activation in hepatocarcinogenesis [113]. 
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Significant over-expression of Notch1 and Notch3 was detected through 
immunohistochemistry in HCCs [114]. In addition, the depletion of Notch3 
by specific shRNAs increased p53 expression and enhanced doxorubicin-
sensitivity by promoting apoptosis. Moreover, a recent study found that 
HBV x protein upregulates key molecules in Notch signaling (Notch1, 
HES1, and Jagged1) [115].  
 
1.2.2 GS-negative Oligodendroglioma (OD) 
Oligodendroglioma (OD) is a low-grade glioma originating from 
oligodendrocytes or, more likely, from glial precursor cells. 
OD is the third most common glioma overall, accounting for 2%–5% of 
primary brain tumors and 5%–18% of all glial neoplasm. OD generally 
occurs in adult age, with an average age at diagnosis of 35, while a low 
percentage (about 6%) arises in children and rarely manifests as fetal 
tumor [116]. OD arises more frequently in males with an overall sex ratio 
male : female of 2.  
While no definite inheritance pattern or known genetic risk factors have 
been documented, occasional familial groupings of oligodendroglioma and 
oligoastrocytoma have been reported [117]. 
The etiology of this cancer is still unknown since no causative 
environmental or lifestyle factors have been unequivocally identified [118].  
It has been observed that losses of portions of chromosomes 1p and 19q 
are a characteristic lesion of OD; this 1p/19q co-deletion is mediated by an 
unbalanced translocation of 19p to 1q: der(1;19) (p10;q10) [119]. About 
25% of anaplastic oligodendrogliomas have deletion of the tumor 
suppressor gene p16 located on the short arm of chromosome 9, while 
mutation of p53 is more typical for astrocytoma.  
Histological criteria for distinguishing OD from astrocytoma remain 
subjective, with significant inter-observer variability; however it has been 
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demonstrated that OD is usually histologically GS negative, whereas GS-
positivity is a specific marker for astrocytes [120].  
Similarly to astrocytoma, OD remains localized to the central nervous 
system (CNS). Extra-CNS metastases (especially to bone) have been 
described, but this is a very rare evenience and occurs in the occasional 
patient only at later stages of the disease. 
Therapeutic approaches for OD rely on surgery and chemotherapy.  
Surgical resection is the main form of therapy for most patients with an 
oligodendroglial tumor; however, because of its infiltrative nature, the tumor 
may frequently be poorly delineated from the normal brain parenchyma, 
making complete resection impossible [116]. 
Chemotherapy of OD was improved in 1988, when the efficacy of the 
combination of procarbazine, lomustine, and vincristine (PCV) was 
demonstrated [121]. Subsequently the efficacy of PCV treatment has been 
demonstrated since approximately two-thirds of patients have either a 
complete response or partial response to PCV. However, the cumulative 
haematological toxicity and gastrointestinal side effects, associated with 
standard PCV, often limit the duration of its administration [118].  
More recently, an alkylating agent, temozolomide, has shown promise, 
although at a lower response rate compared to PCV, as an effective 
chemotherapeutic alternative. Similar to outcome after PCV chemotherapy, 
response is more frequent and with longer duration in patients with 
combined 1p/19q loss. Moreover, the better tolerability and the ease of 
administration of temozolomide as compared to PCV have made 
temozolomide the drug of choice in most institutions.  
Apart from temozolomide and PCV, few agents (i.e. paclitaxel, CPT-11, 
carboplatin, etoposide plus cisplatin), have been investigated but response 
rates are low.  
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Despite the achievement of gross total resection, the recurrence of this 
disease is extremely common and usually occurs several years following 
resection and at the surgical site. Malignant transformation of the 
recurrence to an anaplastic oligoastrocytoma or glioblastoma multiforme 
may occur, although at lower rates compared with typical astrocytomas 
[116]. 
Thus, although the prognosis of OD is better than astrocytomas or other 
gliomas, the overall prognosis is still guarded. The median postoperative 
survival period for patients with oligodendrogliomas ranges from 3 to 17 
years, and although occasional long-term survivors (up to 40 years) have 
been reported, almost all patients die for their disease [122]. 
 
1.2.3 Mesenchymal stem cells interaction with acute 
lymphoblastic leukaemia blasts  
1.2.3.1 Mesenchymal stem cells (MSC) 
Mesenchymal stem cells (MSC) are multipotent stromal cells which have 
the capability to differentiate into several cell types, such as adipocytes, 
chondrocytes and osteoblasts (see Fig. 16).  
During the past decade, a large amount of publications were focused on 
MSC, because of their ability to proliferate ex vivo, their potential for 
multilineage differentiation and their immunomodulatory properties [123].  
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Fig. 16 BM-MSC trasndifferentiation ability (from [123]). 
 
MSC were first isolated from bone-marrow by Friedenstein in 1976 [124]. 
However, MSC are widely distributed in a variety of adult tissues such as 
the umbilical cord, Wharton's jelly, adipose tissue, peripheral blood and the 
lungs, but also in fetal tissues and placenta.  
In adult tissues, MSC are either constantly present or their pool is 
replenished by the migration of bone marrow-derived MSC (BM-MSC) 
[125]. Thus, bone marrow is the main source of MSC extraction, although 
an invasive surgical procedure is required for cell recovery, and the 
percentage of MSC isolated is relatively low (0.001%–0.01%) and inversely 
correlated with the age of the donor [123]. Despite this limitation, once 
isolated, MSC are easy to grow in vitro, without apparent modification of the 
phenotype and/ or loss of function. Generally, MSC are cultured at low 
density (1,500 -3,000 cells/cm2) to avoid differentiation.  
There is still a wide perception in the literature that MSC represent a 
phenotypically heterogeneous population of cells and no distinctive typical 
markers are still available.  
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However, the International Society for Cell Therapy has proposed the 
following criteria for human BM-MSC characterization:  
1. adherence to plastic in standard culture conditions;  
2. expression of surface molecules such as CD73, CD90, and CD105 
in the absence of CD34, CD45, HLA-DR, CD14 or CD11b, CD79a, 
or CD19, as assessed by fluorescence-activated cell sorter 
analysis;  
3. capacity to differentiate into osteoblasts, adipocytes, and 
chondroblasts in vitro [126].  
MSC morphologically appears with a small cell body endowed with a few 
processes that are long and thin. The cell body contains a large, round 
nucleus with a prominent nucleolus (see Fig. 17). 
 
Fig. 17 BM-MSC. Magnification 200x (from [127]). 
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1.2.3.2 Acute lymphoblastic leukaemia (ALL) 
Acute lymphoblastic leukaemia (ALL) is a form of leukaemia that occurs 
more often in childhood, with an incidence peak at 2-5 years of age.  
ALL is generally characterized by gross chromosomal alterations. In B-cell 
disease, these alterations include high hyperdiploidy of at least five 
chromosomes (including X, 4, 6, 10, 14, 17, 18, and 21), hypodiploidy with 
fewer than 44 chromosomes, and recurring translocations [128].  
Many of this chromosomal rearrangements disrupt genes that regulate 
normal haemopoiesis and lymphoid development (i.e., RUNX1, ETV6), 
activate oncogenes (i.e., MYC), or constitutively activate tyrosine kinases 
(i.e., ABL1), hence contributing to malignant transformation (Fig. 18).  
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Fig. 18 Pathogenesis of B-lymphoblastic leukaemia (from [128]) 
 
The treatment of ALL has been markedly improved during the past 40 
years and nowadays the 5-year free disease survival exceeds 90% in the 
child. Treatment typically spans 2–2.5 years, and comprises 3 phases: 
induction of remission, intensification (or consolidation), and continuation 
(or maintenance) [129].  
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The remission-induction therapy is aimed to eradicate the initial leukemic 
cell burden and restore normal haemopoiesis. During this phase 
chemotherapy is based on vincristine and glucocorticoid (prednisolone or 
dexamethasone) combined with one of the three preparation of ASNase 
(for details see 1.1.3 The first anticancer metabolic drug: L-asparaginase 
(ASNase)).  
The intensification-therapy is given after the remission-induction treatment, 
and is aimed to eradicate residual leukemic cells [130]. High-dose 
methotrexate with mercaptopurine is often given, together with frequent 
pulses of vincristine and glucocorticoids, uninterrupted asparaginase for 
20–30 weeks, and reinduction therapy with drugs similar to those used 
during remission-induction therapy. 
The continuation-therapy typically lasts 2 years or longer and comprises 
mainly daily mercaptopurine and weekly methotrexate with or without 
pulses of vincristine and dexamethasone [128]. 
However, some subsets of acute lymphoblastic leukaemia still have an 
adverse prognosis. 
 
1.2.3.3 MSC implication in haematological malignancies 
In the bone-marrow MSC are crucial for the maintenance of the 
hematopoietic microenvironment.  
One of the roles of MSC is the participation in the formation of the 
hematopoietic stem cell (HSC) niche. In fact, in the bone marrow there is a 
structurally unique niche made of MSC–HSC paired populations, tightly 
regulated by local input from the surrounding microenvironment and by 
long-distance cues from soluble factors and the autonomic nervous system 
[131]. MSC generate a number of stromal cells, which have been shown to 
have an impact on HSC behaviour, including adipocytes, pre-osteoblast, 
osteoblasts and chondrocytes [132]. This niche is directly involved in self-
renewal and differentiation of HSC.  
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The role of MSC in tumor is not completely ascertained and conflicting 
opinions have arisen.  
On one side, there are evidences confirming that MSC may allow and 
support tumor growth [123]. For example, it has been recently 
demonstrated that MSC support the growth of chronic lymphocytic leukemic 
(CLL) blast. CLL blasts exhibit low expression of Xc− transporter and, hence, 
low uptake of cystine. MSC, conversely, are able to transport cystine, which 
is converted into cysteine and released into the microenvironment for 
uptake by CLL cells to promote GSH synthesis [67] and, hence, survival of 
CLL blasts. Furthermore, MSC are known to have an anti-apoptotic effect 
on acute promyelocytic leukaemia cells and to promote leukemic cell 
survival. BM-MSC have been shown to play a protective role on leukemic 
cells isolated from acute myeloid leukaemia (AML) and chronic myeloid 
leukaemia (CML) patients, contrasting apoptosis induced by FI700 (FLT3 
inhibitor) and imatinib, respectively [133]. BM-MSC also induce resistance 
to apoptosis in ALL cells exposed to ASNase, through the release of 
asparagine (for details, see 1.1.3 The first anticancer metabolic drug: L-
asparaginase (ASNase)) [66]. 
On the other hand, several studies have shown that BM-MSC can also 
interact with leukemic stem cells (LSC) and exert an inhibitory effect on 
K562 cell line proliferation through Wnt-inhibitor Dickkopf-1 (DKK-1) or by 
inhibiting cell cycle progression. Additionally, BM-MSC can inhibit the 
proliferation of leukemic cells from patients having CML [133].  
It has been proposed that MSC can be friend or foe of cancer cells 
depending on their origin (BM, adipose tissue, cord blood), differentiation 
state (STRO-1+CD56+TNAP−/dim21or total stromal cells), and the type of 
tumor cells they interact with [134] (i.e. acute or chronic leukaemia). 
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CHAPTER 2 
AIM OF THE THESIS 
Considering the importance of Gln in cancer cell metabolism, the aim of my 
thesis is to evaluate the effects of pharmacologically induced Gln 
withdrawal on cancer cell viability, so as to assess if and in which tumors 
this metabolic approach may induce cytotoxicity and, hopefully, cancer 
control. Since mTOR activity is needed for cell proliferation and is often 
over-activated in many kinds of cancer, the effect of Gln depletion on the 
kinase has been also investigated.  
To obtain a severe glutamine depletion, I have combined L-asparaginase, 
targeted to deplete extracellular Gln, with the inhibition of Glutamine 
Synthetase (GS). This double-hit approach was applied first on β-catenin 
mutated human hepatocellular carcinoma (HCC) cells, because (1) the liver 
is rapidly exposed to amino acid variations in blood and (2) a subset of 
HCC present over-expression of GS, caused by activating mutations of β-
catenin. Thus, β-catenin mutations may drive metabolism towards 
“glutamine addiction” and, hence, that β-catenin-mutated HCC should be 
more sensitive to Gln depletion.  
Moreover, to assess if GS expression plays a role in the cell adaptation to 
glutamine depletion, I have also extended the same approach to “GS-
negative” human oligodendroglioma cell lines and to co-cultures of normal 
bone marrow mesenchymal stem cells (MSC) and acute lymphoblastic 
leukaemia cells. 
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1 Cell lines and treatments 
3.1.1 Cell culture 
The human β-catenin mutated HCC HepG2 (a gift of Prof. Giovanni 
Raimondo, Laboratory of Molecular Biology and Hepatology, Department of 
Internal Medicine, University of Messina, Italy) and the HB Huh6 (a gift by 
Dr. Nadia Lampiasi, IBIM C.N.R., Palermo, Italy) cell lines and the β-
catenin wild type HCC Huh7 (a gift by Prof. Giovanni Raimondo, Laboratory 
of Molecular Biology and Hepatology, Department of Internal Medicine, 
University of Messina, Italy) cells were grown in low-glucose (1 g/l) 
Dulbecco’s modified medium (DMEM, EuroClone) supplemented with 4 mM 
glutamine (Gln), 10% fetal bovine serum (FBS) and antibiotics (100 U/ml 
penicillin, and 100 μg/ml streptomycin).  
The paediatric β-catenin mutated HCC HC-AFW1 cell line was isolated 
from a liver neoplasm of a 4-year-old boy culturing primary tumor 
specimens [135] and kindly provided by Prof. Armeanu-Ebinger, 
Department of Pediatric Surgery and Urology, University Children´s 
Hospital, Eberhard Karls University Tübingen, Germany. HC-AFW1 were 
cultured in high-glucose (4.5 g/l) DMEM (EuroClone) supplemented with 2 
mM Gln, 10% FBS and antibiotics.  
HeLa cells, obtained from ATCC, were maintained in high-glucose DMEM 
(EuroClone), enriched with 1 mM sodium pyruvate, 4 mM Gln, 10% FBS 
and antibiotics.  
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The oligodendroglioma (OD) cell line, HOG (provided by Dr. G. Dawson 
University of Chicago, USA), and the glioma cell line, U87 (a gift of Prof. D. 
Parolaro of Universiy of Insubria, Italy) were grown in high-glucose DMEM 
(EuroClone) supplemented with 4 mM Gln, 10% FBS and antibiotics.  
The OD cell line Hs683 (provided by Dr. R. Kiss, University of Bruxelles) 
was grown in low-glucose DMEM (EuroClone) supplemented with 2 mM 
Gln, 10% FBS, antibiotics and 2.1 g/l sodium bicarbonate.  
After thawing, HepG2, Huh6, Huh7, HC-AFW1, HeLa, HOG, U87, and 
Hs683 cultures were not used for more than 12 passages (6-12 weeks 
depending on the cell line). 
Bone-marrow mesenchymal stem cells (MSC) were isolated as described 
by [132], and kindly provided by Dr. Giovanna D’Amico, Centro Ricerca 
Tettamanti, Department of Pediatrics, University of Milano-Bicocca, 
Ospedale S.Gerardo, Monza, Italy. MSC were cultured in low-glucose 
DMEM supplemented with 2 mM Gln, 10% FBS, antibiotics at cell density 
of 3,000 cell/cm2. After thawing, MSC were not used for more than 7 
passages. 
The pre-B acute lymphoblastic leukaemia, RS4;11, REH, and Nalm6, cell 
lines (a gift of Dr. Giovanna D’Amico, Centro Ricerca Tettamanti, 
Department of Pediatrics, University of Milano-Bicocca, Ospedale 
S.Gerardo, Monza, Italy) were grown in RPMI 1960 Advanced medium 
(Invitrogen), supplemented with 4 mM Gln, 10% FBS (for RS4;11 and 
Nalm6) or 20% FBS (for REH), and antibiotics.  
All cells were maintained at 37 °C in an atmosphere of 5% CO2 in air, pH 
7.4.  
For the experiments reported in Fig. 39, cells were incubated in pyruvate- 
and glucose-free DMEM containing 4 mM Gln (Gibco), supplemented with 
1 g/l glucose.  
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3.1.2 Treatments 
Unless otherwise stated, ASNase (E. chrisanthemy ASNase, Erwinase®, 
Crisantaspase, a generous gift of EUSAPharma, an internal division of Jazz 
Pharmaceutics) was used at 1 U/ml, the GS inhibitors methionine-L-
sulfoximine (MSO) and DL-phosphinothricin (PPT) at 1 mM, and the Notch 
inhibitor DAPT at 75μM.  
For the experiments shown in Fig. 19, Fig. 20, Fig. 21, Fig. 22, Fig. 25, Fig. 
26, Fig. 27, Fig. 28, Fig. 29, Fig. 30, Fig. 31, Fig. 36, and Fig. 81 cells were 
washed with Earle’s Balanced Salt Solution (EBSS, composition in mM: 
NaCl 116, KCl 5.3, CaCl2 1.8, MgSO4·7H2O 0.81, NaH2PO4·H2O 0.9, 
NaHCO3 26, glucose 5.5, supplemented with 0.02 % Phenol Red) and 
incubated in DMEM with or without glutamine or GS inhibitors, 
supplemented with dialyzed FBS. For the experiments shown in Fig. 23 and 
Fig. 24 cells were washed and incubated in EBSS for 3 hours. Starved cells 
were then incubated for 1 hour with glutamine (4 mM) and/or essential 
amino acids (EAA) from the MEM EAA solution (Invitrogen). 
For the experiments shown in Fig. 32 and Fig. 33, cells were washed and 
incubated for 6h in EBSS alone or supplemented with glutamine (4 mM) or 
MSO (4 mM) and PPT (4 mM) and/or EAA from the MEM EAA solution 
(Invitrogen). 
Treatment periods and amino acid concentration are detailed for each 
experiment. 
 
3.1.3 Viability assay 
For viability assay of adherent cell lines, cells were seeded in complete 
growth medium in 96-well or 24 well-plates and grown for 24 hours. Growth 
medium was then substituted with fresh medium containing the drugs to be 
tested. For non-adherent cell lines, cells were seeded in 96-well-plates in 
medium containing the drugs to be tested. Cell viability was assessed with 
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resazurin methods [136], incubating cells in a solution of resazurin (44 μM) 
solved in the line-specific medium without FBS. After 1 hour, fluorescence 
was measured at 572 nm with a fluorimeter (EnSpire® Multimode Plate 
Readers, Perkin Elmer). Alternatively, the cytotoxic effects were assessed 
counting cell with a Coulter Z1 particle counter.  
 
3.1.3 Co-culture of MSC and ALL cells 
For co-culture experiments, shown in Fig. 82, MSC were seeded at 3000 
cells/cm2 in complete growth medium. After 48 hours medium was replaced 
with fresh medium containing 2.5 *105 ALL cells and drugs to be tested. 
After 48 hours cells were collected, centrifuged and the pellet was washed 
with phosphate buffered saline (PBS, composition in mM: NaCl 137, KCl 
2.7, Na2HPO4·2H2O 10, KH2PO4 2, pH 7.4) and resuspended in 300 μl of 
PBS containing 20 μg/ml propidium iodide, 10 μg/ml ribonuclease A, and 
0.1% Nonidet P-40. After 1h-staining in the dark at 4°C, the samples were 
analyzed by means of a FACSCanto cytofluorimeter (Becton & Dickinson, 
San Jose, CA) equipped with a doublet discrimination module. 100,000 
cells were analyzed for each experimental condition. Flow cytometric data 
analysis was performed using the FACSdiva software. 
 
3.2 Gene and protein expression 
3.2.1 qRT-PCR 
Gene expression was evaluated with RT-qPCR. 1 μg of total RNA, isolated 
with GenElute™ total RNA Miniprep Kit (Sigma, Italy), was reverse 
transcribed as described previously [136]. For real time PCR (35 cycles), 
cDNA was amplified with GoTaq® qPCR Master Mix (Promega, USA) 
along with the primers (5 pmol each) reported in Table1. Quantitative PCR 
was performed in a 36 well Rotor Gene 3000 (Corbett Research, Rotor-
Gene™ 3000, version 5.0.60, Mortlake, Australia). Each cycle consisted of 
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a denaturation step at 95 °C for 30 s, followed by separate annealing (30 s, 
55-58 °C) and extension (30 s, 72 °C) steps. Fluorescence was monitored 
at the end of each extension step. A no-template, no-reverse transcriptase 
control was included in each experiment. At the end of the amplification 
cycles a melting curve analysis was added. Data analysis was made 
according to the Relative Standard Curve Method [137].  
 
 
GENE PRIMERS 
GLUL 
(Glutamine Synthetase) 
for 5’ TCATCTTGCATCGTGTGTGTG 3’ 
rev 5’ CTTCAGACCATTCTCCTCCGG 3’ 
ASNS 
(Asparagine Synthetase) 
for 5’ GATTGCCTTCTGTTCAGTGTCT 3’ 
rev 5’ GGGTCAACTACCGCCAACC 3’ 
SLC38A2, SNAT2 
(Solute carrier family 38 
member 2) 
for 5’ ATGAAGAAGGCCGAAATGGGA 3’ 
rev 5’ TGCTTGGTGGGGTAGGAGTAG 3’ 
SLC1A5, ASCT2 
(Solute carrier family 1 
member 5) 
for 5’ TGGTCTCCTGGATCATGTGG 3’ 
rev 5’ TTTGCGGGTGAAGAGGAAGT 3’ 
SLC6A14, ATB0+ 
(Solute carrier family 6 
member 14) 
for 5’ GCTGCTTGGTTTTGTTTCTCCTTGGTC 3’ 
rev 5’ GCAATTAAATGCCCCATCCAGCAC 3’ 
c-MYC 
for 5’ GCTGCCAAGAGGGTCA 3’ 
rev 5’ CGCACAAGAGTTCCGTAG 3’ 
HES-1 
for 5’ ACGACACCGGATAAACCAAA 3’ 
rev 5’ CGGAGGTGCTTCACTGTCAT 3’ 
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CTNNB1 
(β-catenin) 
for 5’ CCTCTGATAAAGGCTACTGTTGGAT 3’ 
rev 5’ CTGATGTGCACGAACAAGCA 3’ 
CCND1 
(cyclin D1) 
for 5’ CCCTCGGTGTCCTACTTCAA 3’ 
rev 5’ AGGAAGCGGTCCAGGTAGTT 3’ 
GLS1 
(glutaminase 1) 
for 5’ GCTGTGCTCCATTGAAGTGA 3’ 
rev 5’ GCAAACTGCCCTGAGAAGTC 3’ 
CHOP 
for 5’ CTTCTCTGGCTTGGCTGACT 3’ 
rev 5’ TCCCTTGGTCTTCCTCCTCT 3’ 
RPL-15 
(ribosomal protein L15) 
for 5’ GCAGCCATCAGGTAAGCCAAG 3’ 
rev 5’ AGCGGACCCTCAGAAGAAAGC 3’ 
 
Table 1 Primers  
 
3.2.2 Western Blot 
After the experimental treatments, cells were rinsed twice in PBS with Ca2+ 
and Mg2+ and lysed in a buffer containing 20 mM Tris-HCl, pH 7.5, 150 mM 
NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4,1 mM NaF, 2 
mM imidazole, and a cocktail of protease inhibitors (Complete, Mini, EDTA-
free, Roche). Lysates were transferred in Eppendorf tubes, sonicated for 
5s, and centrifuged at 12000g for 10 min at 4 °C. After quantification with 
the Bio-Rad protein assay the equivalent of 30 μg of proteins, was mixed 
with Laemmli buffer 4x (250 mM Tris-HCl, pH 6.8, 8% SDS, 40% glycerol, 
0.4 M DTT), warmed at 95°C for 5 min, and loaded on a 10% gel for SDS-
PAGE. After electrophoresis, proteins were transferred to PVDF 
membranes (Millipore—Immobilon-P). Non-specific binding sites were 
blocked with an incubation of 2 hours at RT in 5% non-fat dried milk in 
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TBS-Tween solution. The blots were then incubated at 4 °C overnight with 
the following antibodies diluted in a 5% BSA TBS-Tween solution: anti 
p70S6K1 phospho T389 (rabbit, monoclonal, 1:1000, Cell Signaling), anti 
p70S6K1 phospho T421/S424 (rabbit, monoclonal, 1:1000, Cell Signaling), 
anti p70S6K1 total (mouse, monoclonal, 1:1000, Cell Signaling), anti-eIF2α 
phospho S51 (mouse, monoclonal,1:1000, Abcam), anti-GS (mouse, 
monoclonal, 1:1500, BD, Transduction Laboratories), anti-β-catenin 
(mouse, monoclonal, 1:1000, Dako), anti-ASNS (rabbit, polyclonal, 1:1000, 
Santa-Cruz Biotecnology), anti-GADPH (rabbit, polyclonal, 1:4000, Sigma), 
anti-β-tubulin (mouse, polyclonal, 1:1000, Santa-Cruz Biotecnology). After 
washing, blots were exposed for 1 hour at room temperature to HRP-
conjugated anti mouse or anti-rabbit antibody (Cell Signaling Technology), 
diluted 1:10000 in blocking solution. Immunoreactivity was visualized with 
Immobilon Western Chemiluminescent HRP Substrate (Millipore). 
 
3.2.3 Immunofluorescence 
To study the subcellular distribution of β-catenin we used 
immunofluorescence. Briefly, HCC cells were seeded on 4-chamber 
CultureSlides (Falcon, Becton & Dickinson Company, San Jose, CA) at a 
density of 4*104 cells/cm2. When 70% of confluence was reached, cells 
were rinsed twice in PBS and fixed for 10 min in 3.7% paraformaldehyde in 
PBS. After two further rinses, cells were permeabilized for 7 min in 0.1% 
Triton X-100 in PBS. Cells were then incubated for 1 hour in blocking 
solution (5% of BSA 10% of goat serum, and 0.3 M glycine in PBS) 
followed by an overnight incubation at 4 °C with anti-β-catenin monoclonal 
antibody (DakoCytomation, M35359, 1:200 in PBS 5% BSA), two washes 
in PBS, and an additional 1hour-incubation with an Alexa Fluor 488 anti-
rabbit IgG antibody (Invitrogen, Paisley, UK, 1:400). After one rinse, cells 
were incubated for 30 min with a 100 μg/ml RNAase A solution, and then 
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with a 1 μg/ml solution of propidium iodide (PI) in PBS for 10 min to stain 
nuclei. Cells were observed with a confocal microscope Zeiss® 510 LSM 
Meta (Carl Zeiss SpA, Arese, Milan, Italy), using an oil 60x objective. λex of 
488nm and 540nm and λem of 545nm and 595 nm were used for Alexa 
Fluor 488 and propidium iodide, respectively. 
 
3.3 Amino acid analysis 
3.3.1 Amino acid extraction 
The intracellular content of amino acids was determined as previously 
described [138] with minor modifications. Briefly, cell monolayers were 
washed twice with ice-cold PBS, extracted in a solution of acetic acid (6.6 
mM) in ethanol and processed for protein determination with the Lowry 
method. After lyophilization, samples were reconstituted in LiOH buffer (pH 
2.2). For serum amino acid analysis, sera were deproteinized with 10% 
(w/v) of sulfosalicilic acids (SSA) on ice for 30 min. Then, samples were 
centrifuged at 12000g for 10 min at 4 °C, and supernatants were mixed with 
1 volume of LiOH buffer (pH 2.2). For tissue amino acid extraction, liver and 
tumor samples were homogenized in 6.6 mM solution of acetic acid in 
ethanol with an high-speed drive motor for small volumes homogenizer 
(Ingenieurbϋro CAT, M Zipperer GmbH, Germany) for 30 s on ice. 
Afterwards, samples were centrifuged at 12000g for 10 min at 4 °C, the 
supernatant was collected, lyophilized and reconstituted in LiOH buffer (pH 
2.2).  
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3.3.2 Amino acid determination 
The intracellular content of the single amino acids was determined by 
HPLC analysis with a Biochrom 20 amino acid analyzer (Amersham 
Pharmacia Biotech, UK), employing a high resolution column (Bio 20 Peek 
Lithium) and the physiological fluid chemical kit (Amersham Pharmacia 
Biotech) for elution. The column effluent was mixed with ninhydrin, passed 
through the high-temperature reaction coil and read by the photometer unit. 
Data are expressed as nmol/mg of proteins, mmol/l serum or nmol/mg of 
tissue.  
 
3.4 Amino acid transport and protein synthesis 
3.4.1 L-Leu uptake 
The initial influx of L-Leu was measured in 96-well multidish plates (Falcon, 
Becton Dickinson Biosciences, Franklin Lakes, NJ, USA) where 20,000 
cells/well had been seeded 24 hours earlier. Before the experiments cells 
were rinsed and incubated for 1 hour in EBSS with Tris-HCl at pH 7.4 
supplemented with 5 μg/ml cycloheximide. Then, cells were rinsed twice 
with 200 μl of EBSS Na+-free and incubated in EBSS, with or without Na+, 
supplemented with L-[4,5-3H] Leu (10 μM, 10 μCi/ml, Amersham 
Biosciences) and with specific inhibitors of system ATB0+ and system A. 
After 2 min, multiwell dishes were washed twice with ice-cold urea (300 
mM) and cell monolayers were extracted with 50 μM of cold absolute 
ethanol. The extracts were added to 200 μl of scintillation fluid and counted 
with a Wallac Trilux2 liquid scintillation spectrometer (Perkin-Elmer, Boston, 
MA, USA). Transport values were normalized for the cell protein, 
determined directly in the well with a modified Lowry procedure and 
measured with a Wallac Victor2 Multilabel Counter (Perkin-Elmer). 
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L-Leu transport has been characterized using the following inhibitors to 
discriminate the transporter subtypes: L-Leu (2 mM) ; α-methyl-DL-
tryptophan (αMLT, 2.5mM); D-serine (D-Ser, 2.5mM); N-α-
methylaminoisobutyric acid (MeAIB, 2.5mM).  
Transport assay under Na+-free conditions was performed in a modified 
EBSS in which NaCl was replaced by N-methyl-Dglucamine chloride and 
pH kept at 7.4 with Tris–HCl.  
 
3.4.2 Protein synthesis 
L-[4,5-3H]leucine (10 μCi/ml, Amersham Biosciences) was added to the 
incubation medium during the last 45 min of incubation. At the end of the 
incubation, cells were washed with PBS and extracted with a 6.6 mM 
solution of acetic acid in ethanol. After discarding of the acid-soluble 
fraction, proteins were suspended in 150 μl of 5% sodium-deoxycholate in 
1 N NaOH. While 50 μl were used for the determination of total proteins 
with Lowry method, scintillation fluid was added to the remaining aliquot 
and the incorporated radioactivity counted with a scintillation spectrometer 
(Wallac Microbeta Trilux counter). Data were expressed as CPM/mg 
prot/min.  
 
3.5 Gene manipulation 
3.5.1 β-catenin silencing 
HepG2 and Huh-6 cells were transfected with a scrambled siRNA (ON-
TARGETplus Non-targeting Pool) or with a siRNA targeting β-catenin (ON-
TARGETplus SMARTpool, CTNNB1, Thermo Scientific DharmaFECT) 
following with modifications the procedure described by Cairo et al. [139]. 
Briefly, HepG2 and Huh-6 cells were seeded in complete growth medium 
without antibiotics in 12-well plates, at a density of 1.5*105/well and 
2.5*104/well, respectively. After 24 hours cells were incubated in a FBS- 
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and antibiotic-free medium containing DharmaFECT transfection reagent 
and the siRNAs. After further 16 hours medium was replaced with fresh 
complete growth medium and cultures underwent the experimental 
treatments. 
 
3.5.2 Luciferase assay 
HCC cells were seeded in 6-well-plates in standard growth medium. After 
24 hours cells were washed with PBS and incubated in DMEM in the 
presence or in the absence of glutamine without serum and antibiotics. 
After 24 hours, the cells were transiently transfected with the reporter 
construct TOPflash (Upstate, Lake Placid, NY), kindly provided by Prof. 
Monga, University of Pittsburgh. TOPflash has three copies of the Tcf/Lef 
sites upstream of a thymidine kinase (TK) promoter and the firefly 
luciferase gene. All transfections were performed using 1.8 µg of TOPflash 
plasmids and FuGene HD reagent (Roche, Indianapolis, IN). To normalize 
transfection efficiency in reporter assays, the cells were cotransfected with 
0.2 µg of the internal control reporter Renilla reniformis luciferase under the 
TK promoter (pRL-TK; Promega, Madison, WI). 20 hours after TOPflash 
transfection, luciferase assay was performed, using the Dual Luciferase 
Assay System kit, in accordance with the manufacturer's protocols 
(Promega). Luminescence was detected with a Wallac Microbeta Trilux 
(Perkin Elmer, Wellesley, Ma, USA). Relative luciferase activity (in arbitrary 
units) was reported as fold induction after normalization for transfection 
efficiency.  
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3.6 In vivo experiments 
3.6.1 Animals and treatments 
Experiments in athymic nude nu/nu mice were performed at the Laboratory 
of Genetic Engineering for the Production of Animal Models (LIGeMa) at 
the Animal House of the University of Firenze. In the experiment shown in 
Fig. 47, Fig. 48, and Fig. 49 male five-weeks old mice (Harlan Italy, Udine, 
Italy) were treated with intraperitoneal (i.p.) injections of ASNase (5 U/ml) 
and MSO (10 mg/kg), both in 0.9% NaCl, or vehicle alone, MSO was 
injected 3 hours after ASNase injection. Treatment was performed three 
times a week for three weeks, after which peripheral blood (PB) and liver 
were collected for analysis. After collection PB was centrifuged and serum 
was frozen (-80°C).  
In the experiment shown in Fig. 50, Fig. 51, Fig. 52, Fig. 53, Fig. 54, and 
Fig. 55 mice were subcutaneously (s.c.) injected with HepG2 cells (2.5 x 
106 cells). After 8 days, mice were i.p. treated with ASNase and MSO, 
alone or in combination. Tumor growth was monitored for 19 days by 
external measurement using a caliper and tumor volume was calculated by 
applying the ellipsoid equation. 3 hours after the last MSO injection, which 
corresponds to 6 hours after ASNase injection, mice were sacrificed, and 
PB, tumor masses and livers were collected for analysis. After collection PB 
was centrifuged and serum frozen. In the experiment shown in Fig. 56 and 
Fig. 57 mice were s.c. injected with 2.5 x 106 cells of HepG2 (left flank) or 
Huh7 cells (right flank). After two weeks the combined treatment with 
ASNase and MSO (see above) started. Control animals were injected with 
vehicle alone. Tumor growth was monitored by external measurement 
using a caliper and tumor volume was calculated by applying the ellipsoid 
equation. Three weeks after treatment, 3 hours after the last MSO injection 
(6 hours after ASNase injection) mice were sacrificed, and tumor masses 
dissected and weighted. 
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In the experiment shown in Fig. 64, Fig. 65, Fig. 66, and Fig. 67, HC-AFW1 
cells were engrafted in NOD.Cg-Prkdcscid IL2rgtmWjl/Sz (NSG) mice, 
purchased from Charles River (Sulzfeld, Germany) and bred in the 
Department of Pediatric Surgery and Pediatric Urology, University 
Children’s Hospital, Tübingen, Germany. Eight-week-old mice were s.c. 
injected with 2*106 cells and kept in filter-top cages at 22°C, 60% humidity. 
Sterilized food and water were accessible ad lib. After two weeks mice 
were treated as described above with ASNase, MSO or ASNase + MSO. 
Tumor length, width and height were measured every 3 days and tumor 
volumes were calculated by applying the ellipsoid equation. Mice were 
weighted every 3 days. After 10 days of treatment mice were sacrificed and 
PB, tumors and livers were explanted for further analysis.  
Animals received human care and study protocolos comply with the 
institutional guidelines for animal welfare. 
 
3.6.2 GS activity 
GS activity was assayed measuring the γ-glutamyltransferase activity of the 
enzyme [140]. Tissues were lysed in 500 μl of a solution containing 50 mM 
imidazole-HCl, pH 6.8, 0.5 mM EDTA, 1 mM DTT, supplemented with 
protease inhibitors (Complete, Mini, EDTA-free, Roche), transferred into a 
1.5 ml microtube, sonicated in ice (Sonicator Ultrasonic Processor XL, 
Misonix), and centrifuged at 12000g, 30 min, 4°C. After quantification (Bio-
Rad Protein Assay), protein concentration of the supernatant was adjusted 
to 1 μg/μl. An aliquot of 150 μl was used for the assay in a mixture (final 
volume 300 μl) consisting of 50 mM imidazole-HCl (pH6.8), 50 mM Gln, 25 
mM hydroxylamine, 25 mM sodium arsenate, 2 mM MnCl2, and 0.16 mM 
ADP. After incubation at 37°C for 30 min, the reaction was stopped adding 
600 μl of a solution containing 2.42% FeCl3 and 1.45% TCA in HCl 1.82%. 
Precipitates were removed by centrifugation (2,000 rpm for 5 min) and 
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supernatants were read at 540 nm using a spectrophotometer (Helios-γ, 
Spectronic Unicam). Values of GS activity, expressed as pmol/min/μg 
protein of γ-glutamylhydroxamate, were calculated with a calibration curve 
using aliquots of the product. 
 
3.6.3 Histological evaluation 
The tumor samples were routinely fixed in buffered formalin and embedded 
in paraffin. Sections (4 µm) were stained with haematoxylin - eosin for 
histological diagnosis and examined according to predefined histological 
variables. Immunohistochemical analyses were performed on all available 
specimens using the following primary antibodies: anti β-Catenin (BD 
Transduction Laboratories, CA, USA; 1:1000) and anti Glutamine-
Synthetase (BD Transduction Laboratories, CA, USA; 1:10000). After 
deparaffinization and rehydration, sections were treated with 3% hydrogen 
peroxide. For antigen retrieval, sections were immunostained with HRP 
Polymer (Advance HRP Kit, Dako) in accordance with the manufacturer’s 
specifications. 3-31Diaminobenzidine (DAB) was used for staining 
development. In negative controls, normal serum replaced the primary 
antibody.  
 
3.6.4 Ki67 index 
Deparaffinized tissues were exposed to citrate buffer pH 6.0 at 90 °C for 20 
min. Endogenous perodixase was blocked with 3% H2O2 for 10 min in dark. 
After washing, non-specific binding sites were blocked with an incubation of 
1h at room temperature in 3% goat serum (DAKO) and the tissues were 
then exposed at 4°C for 20 min to the anti-Ki67 antibody (mouse 
monoclonal, 1:75, DAKO) diluted in 5% bovine serum albumin TBS Tween 
solution. After washing, HRP-conjugated antibody (HRP One-Step polymer 
anti mouse/rabbit/rat, ZYTOMED) was added and incubated for 45 min at 
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room temperature. Incubation of 10 min with DAB (DAB substrate kit for 
peroxidase, SK-4100, Vector Laboratories) was performed to detect the 
signal. Slides were counterstained in hematoxylin (Mayer´s Hemalaun, 
AppliChem) for 10 s and rinsed in running tap water for 10 min. Ki67 index 
was calculated counting a minimum of 10 randomly selected high-power 
(x40) fields containing representative sections of tumor and calculated as 
the percentage of positively stained cells to total cells [141]. 
 
3.7 Statistics 
Data were expressed as means ± SD. For statistical analysis, two-tail 
Student’s t test for unpaired data or one-way ANOVA were used, whenever 
appropriate. GraphPad Prism 5.0™ was used for all the statistical analyses 
and p values < 0.05 were considered statistically significant. 
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CHAPTER 4 
RESULTS AND DISCUSSION 
 
4.1 mTOR activity is modulated not only by essential 
amino acids (EAA) intracellular content 
Mammalian target of rapamycin (mTOR) plays a pivotal role in the control 
of cell growth and protein synthesis. Many upstream signals converge on 
the regulation of this kinase, such as growth factors, energy status (via 
AMPK pathway), hypoxia and glucose content [142]. However, the main 
factor which determines mTOR activation is definitely amino acid, and in 
particular leucine, availability [143]. Also glutamine is critical for mTOR 
activation, although there are contradictory opinions on the role of this 
amino acid in mTOR stimulation.  
Recently, it has been proposed that glutamine has an indirect role on 
mTOR activation by allowing leucine entry through a tertiary active 
transport [45]. However, due to its importance as nitrogen donor and 
anaplerotic substrate, we hypothesized that glutamine may directly 
influences mTOR activity.  
 
4.1.1 Glutamine regulates mTOR independent on EAA content 
4.1.1.1 Glutamine depletion down-regulates mTOR in a dose and 
time dependent manner 
To evaluate the effects of glutamine (Gln) on mTOR activity HepG2 cells 
were incubated in DMEM supplemented with decreasing concentrations of 
Gln, from 4 mM to 0 for 24 hours. mTOR activity was assessed by the 
phosphorylation of S6K1 at the sites: T389 and T412 (for the p70 and p85 
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isoforms, respectively), which are the selective target of the mTORC1 
complex, and T421/S424 and T444/S447 (for p70 and p85 isoforms, 
respectively), which are the target of both mTORC1 and MAP kinases 
[144]. Western blot analysis revealed that mTOR activity decreases in a 
Gln-dependent manner (Fig. 19). However the activity was not completely 
suppressed, since the phosphorylation of S6K1 is still visible in the absence 
of Gln. S6K1 phosphorylation was suppressed by rapamycin, confirming its 
dependence upon mTORC1 (data not shown). Glutamine Synthetase (GS) 
expression was increased by Gln depletion. Since GS protein abundance is 
regulated by Gln intracellular concentration [52, 53], this pattern suggests a 
progressive fall of intracellular Gln content during the incubation in media 
supplemented with decreasing concentrations of the amino acid.  
 
 
Fig. 19 mTOR activity was regulated by Gln concentration. The 
expression of p70S6K1 (phospho T389 and T421/S424), p85S6K1 
(phospho T412 and T444/S447), S6K1 (total), and Glutamine Synthetase 
(GS) was assessed in HepG2 cells incubated for 24 hours in DMEM 
supplemented with 10% dialysed FBS at the following Gln concentrations 
(mM): 4, 2.26, 1.25, 0.71, 0.4, 0.22, 0.125 and 0. β-tubulin was used as a 
loading control. The experiment was repeated three times with comparable 
results. 
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Recently, it was proposed that, in HeLa cells, Gln stimulates mTORC1 
increasing the intracellular availability of leucine through a transport 
exchange mechanism [45]. However, in that paper intracellular leucine was 
not measured. To ascertain if the modulation of mTOR was due to Gln 
availability itself or to a consequent decrease in leucine (Leu) content, we 
measured intracellular amino acids in HepG2 cells incubated in the 
presence (4 mM) or in the absence (0 mM) of Gln for 24 hours. HPLC 
analysis revealed that Gln starvation caused a clear cut decrease of 
intracellular Gln, Glu and Ala, but, paradoxically, a significant increase of 
the essential amino acids (EAA) and, in particular Leu, content was 
detected (Fig. 20), suggesting that intracellular leucine does not appear to 
be the only factor that regulates mTORC1.  
 
 
Fig. 20 Leucine intracellular content increased in the absence of 
extracellular Gln. HepG2 cells were incubated for 24 hours in DMEM 
supplemented with 10% dialyzed FBS and 4 mM (black bars) or 0 mM 
(gray bars) Gln and cell content of amino acids were determined as 
described in Methods. Data are means ± SD of three independent 
experiments. § p<0.05 vs. control (4 mM Gln). 
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Time course of changes in mTORC1 activity during Gln starvation indicated 
that the activity of the kinase was almost abolished at earlier times (3-9 
hours) but seemed to increase at later times (24-48 hours), although it 
remained lower compared to control (4 mM Gln) (Fig. 21 A). Also in HeLa 
cells, Gln depletion caused a biphasic changes in mTOR activity, which 
decreased at earlier times and showed a partial restoration at later times 
(Fig. 21 B).  
 
 
Fig. 21 mTOR activity was partially restored at later times of Gln 
starvation. Western Blot of S6K1 (phospho T389 and T412) and S6K1 
total was performed in HepG2 (A) and HeLa (B) cells incubated for the 
indicated times with DMEM supplemented with 10% dialysed FBS without 
Gln. The experiment was repeated three times with comparable results. 
 
To understand the reason of the partial restoration of mTORC1 activity, 
amino acid content was analysed in both HepG2 and HeLa cells. In both 
cell lines Gln and Glu continued to decrease during the experiment, while 
Leu content increased, reaching levels higher than control (Fig. 22). The 
behaviour of Leu was shared by other EAA (not shown, see [145]).This 
observation suggests that the increase of Leu may be sensed upstream of 
mTOR and partial rescues kinase activity. However, given that activity 
restoration was not complete, we speculate that two signals, one from Leu 
and the other from Gln, are required to attain a full mTOR activation.  
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Fig. 22 Leucine content increased at later times of Gln deprivation. 
Amino acids content was determined, as described in Methods, in HepG2 
(A) and HeLa (B) cells incubated for the indicated times with DMEM 
supplemented with 10% dialyzed FBS without Gln. A single representative 
experiment is shown.  
 
4.1.1.2 Essential Amino Acids alone are not able to fully activate 
mTOR 
To confirm the hypothesis that two signals, one from Gln and the other from 
EAA, are needed for a complete mTOR activation, we incubated both 
HepG2 and HeLa cells in unsupplemented saline solution (EBSS) for 3 
hours. This condition led to a marked reduction of mTOR activity, since the 
phosphorylation of S6K1 was not detectable at all (Fig. 23). In HepG2 cells, 
the restitution for 1 hour of Gln (4 mM) to starved cells does not caused any 
increase in the phosphorylation of S6K1. Likewise, the restitution of EAA, in 
absence of Gln, was not able to increase the phosphorylation of S6K1 even 
when added at doubled (2x) or tripled (3x) concentration than standard 
growth medium. Instead, only the simultaneous restitution of Gln and EAA 
(1x) restored mTOR activity (Fig. 23 upper). At variance with HepG2 cells, 
when Gln (4 mM) alone or EAA alone were restored to starved cells, a 
slight increase in the phosphorylated status of S6K1 was observed in HeLa 
cells. However, also in HeLa cells, like in HepG2, a complete mTOR 
activation was detected only when both Gln and EAA were simultaneously 
administered (Fig. 23 bottom).  
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Fig. 23 Gln and EAA alone were not able to fully activate mTOR. 
Western Blot of S6K1 (phospho T389 and T412) and S6K1 total was 
performed in HepG2 (upper) and HeLa (bottom) cells. Growth medium was 
washed and replaced with unsupplemented saline solution (EBSS) for 3 
hours. Cells were then incubated in fresh EBSS or in EBSS supplemented 
with 4 mM Gln and/or Essential Amino Acids (EAA, 1x, + at the 
concentration present in DMEM) or at double (2x, ++) or triple (3x, +++) 
concentrations. The incubation was prolonged for 1 hour. The experiment 
was repeated three times with comparable results.  
 
By a parallel analysis of amino acid content in both cell lines, we found that 
the Leu content was comparable when EAA (1x) were added alone or in 
the presence of Gln (Fig. 24), confirming that the role of Gln in mTOR 
regulation is not restricted to favour Leu entry as previously reported [45]. 
Furthermore, when EAA were added at double or triple concentrations 
compared to those present in DMEM, an increased cell content of Leu was 
detected (Fig. 24), although mTOR activation was only sub-maximal. 
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Fig. 24 Intracellular Leu content was not dependent on the presence 
of extracellular Gln. Amino acid content was determined, as described in 
Methods, in HepG2 (upper) and HeLa (bottom) cells. Growth medium was 
washed and replaced with unsupplemented saline solution (EBSS) for 3 
hours.Cells were then incubated in fresh EBSS or in EBSS supplemented 
with 4 mM Gln and/or Essential Amino Acids (EAA, 1x at the concentration 
present in DMEM) or at double, 2x, or triple, 3x concentrations). The 
incubation was prolonged for 1 hour. A single representative experiment is 
shown.  
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These data, in accordance with previous reports [45, 146], confirms that 
Gln alone is not able to determine complete mTORC1 activation. However, 
the evidence that high extracellular Gln levels reduce EAA cell content in 
both HepG2 and HeLa cells suggests that the transport interaction between 
Gln and EAA is more complex that the tertiary transport proposed in 
previous reports [45, 147, 148]. In fact, in accordance to the tertiary 
transport theory, Leu and other EAA influx should be energized by the 
efflux of Gln previously accumulated through a secondary active transport. 
Instead, from these data it seems more likely that, at least in these models, 
Gln and Leu share, in a competitive manner, a secondary active 
transporter, endowed with a sufficient broad specificity. A potential 
candidate could be the ATB0+ carrier (see below), an active secondary 
transporter, encoded by the gene SLC6A14, able to mediate the uptake of 
18 proteinogenic amino acids and, in particular, exhibiting high affinity for 
the most important mTOR stimulating amino acids, Leu and Gln [149]. 
However, considering that the recovery of mTOR activity started after 24 
hours from Gln depletion, it cannot be excluded a role of the autophagic 
process in the increase of Leu and other EAA cell levels.  
 
4.1.2 ATB0+ transporter may be involved in mTOR stimulation 
To evaluate the involvement of ATB0+ in Gln and Leu competitive uptake, 
first we examined SLC6A14 mRNA abundance in Gln deprived HepG2 
cells. After 6 hours of Gln starvation, the transporter was 4-fold higher than 
in control cell (maintained with 4 mM Gln), and this induction persisted after 
24 hours (Fig. 25).  
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Fig. 25 ATB0+ was induced in Gln starved HepG2 cells. SLC6A14 
expression was analyzed by RT-qPCR. HepG2 cells were incubated in the 
absence of Gln for the indicated times. Relative SLC6A14 mRNA 
abundance was normalized to RPL-15 and expressed as Arbitrary Units.  
 
Considering that the tertiary transport theory should involve the system A 
carriers, such as SNAT2 transporter (encoded by SLC38A2 gene), coupled 
with the exchanger ASCT2 transporter (encoded by SLC1A5 gene), the 
expression of these two transporters was evaluated in Gln deprived HepG2 
cells. RT-qPCR analysis revealed that both SLC38A2 and SLC1A5 doubled 
after Gln withdrawal (Fig. 26 A and B respectively). The induction of the 
system A transporter is not surprising since it was previously demonstrated 
that nutritional stress may induce this carrier [136, 150]. 
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Fig. 26 SNAT2 and ASCT2 were induced after Gln withdrawal. 
SLC38A2 (A) and SLC1A5 (B) mRNA levels were analyzed by RT-qPCR. 
HepG2 cells were incubated in the absence of Gln for the indicated times. 
Relative mRNA abundance was normalized to RPL-15 and expressed as 
Arbitrary Units. 
 
Then, to evaluate the transport system involved in Leu uptake in Gln 
starved cells, radio-labelled L-[4,5- 3H]-leucine uptake was measured. The 
influx of 10 μM Leu, a concentration near to the Km of ATB0+ and LAT 
transporters [151], was measured in the presence or in the absence of Na+ 
in cells incubated in the presence (4 mM) or in the absence of Gln for 8 
hours. Cells were washed and incubated for 1 hour in EBSS to cause 
amino acid efflux in order to empty the cells and minimize trans-effects that 
could modify carrier activities. Since EBSS incubation induces system A 
carriers [150], cycloheximide (5 μg/ml) was added to block protein 
synthesis during this further incubation.  
In Gln-fed cells, Na+-dependent transport was calculated subtracting the 
influx measured in the absence of Na+ from that measured in the presence 
of the cation, and found to correspond to 180 pmol/mg prot/min (roughly the 
27% of total). Saturating entry routes for leucine with high concentrations of 
the amino acid (2 mM), it was possible to estimate diffusion (18%).  
Adding the ATB0+ inhibitors [149], α-methyl-DL-tryptophan (αMLT, 2.5 mM) 
or D-serine (D-Ser, 2.5 mM), the Na+-dependent transport was inhibited, 
while the Na+-independent component was inhibited by αMLT only (Fig 27). 
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Eventually, Leu transport was measured in the presence of a selective 
inhibitor of system A, N-methyl,α-methylaminoisobutyric acid (MeAIB, 2.5 
mM). This condition did not produce any significant change in Na+-
dependent Leu uptake compared to control (Fig 27), suggesting that in Gln 
fed cell Leu Na+-dependent uptake was referable to a MeAIB-resistant 
system.  
Thus, in Gln-fed HepG2 cells Leu uptake is mainly mediated by diffusion 
(18%) and by the Na+-independent system L (55%), however a small 
percentage of Leu uptake is effectively mediated by the Na+-dependent 
system ATB0+ (27%).  
 
 
Fig 27 Leu uptake in Gln fed cells was attributable to Na+-dependent 
MeAIB-resistant systems. Cells were incubated in DMEM with 4 mM Gln 
for 8 hours. DMEM was then replaced with EBSS supplemented with 
cycloheximide (5 μg/ml) for 1 hour. Then cells were incubated for 2 min in 
EBSS supplemented with L-[4,5-3H] Leu (10 µM) with (white) or without 
(black) Na+, in the absence (control) or in the presence of the following 
inhibitors: 2 mM Leu, 2.5 mM αMLT, 2.5 mM D-Ser, 2.5 mM MeAIB. Values 
are the means of five independent determinations with SD shown. * p< 0.05 
vs. cells incubated without Na+. 
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Also in Gln deprived cells a Na+-dependent uptake was observed (Fig. 28), 
which was doubled in relative terms compared with Gln-fed cells. However, 
in Gln deprived cells αMLT did not completely inhibit the Na+-dependent 
transport, suggesting the involvement of another Na+-dependent system in 
Leu uptake.  
Consistently, a marked inhibition of Na+-dependent transport was observed 
in the presence of MeAIB, suggesting that, under Gln deprivation, an 
induction of system A had occurred.  
Hence, in Gln-deprived HepG2 cells Leu uptake is still mediated by 
diffusion (18%), but the contribution of Na+-independent system L decrease 
(35%) and on the other hand there is an increase of the uptake by Na+-
dependent systems ATB0+ (38%) and A (6%).  
These data confirm the hypothesis that Gln and Leu may compete for 
ATB0+ mediated uptake, explaining why, in the absence of extracellular 
Gln, the cell content of Leu increased. Yet, it was not possible to 
discriminate if the increased Na+-dependent uptake observed in Gln starved 
cells was referable only to the induction of system A or of both systems A 
and ATB0+. However, due to the low affinity of system A for Leu, the 
increase in amino acid content observed in Gln deprived cells is likely still 
referable to the ATB0+ transporter, which has high affinity for Leu (Km= 12 
μM [151]). Thus, the system may be involved in mTOR activation.  
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Fig. 28 Leu Na+-dependent uptake in Gln deprived cells. Cells were 
incubated in DMEM without Gln for 8 hours; DMEM was then replaced with 
EBSS supplemented with cycloheximide (5 μg/ml) for 1 hour. Then cells 
were incubated for 2 min in EBSS supplemented with L-[4,5-3H] Leu (10 
µM) with (white) or without (black) Na+, in the absence (control) or in the 
presence of the following inhibitors: 2 mM Leu, 2.5 mM αMLT, 2.5 mM D-
Ser, 2.5 mM MeAIB. Values are means of five independent determinations 
with SD shown. * p< 0.05 vs. cells incubated without Na+. 
 
4.1.3 Glutamine Synthetase inhibitors activate mTORC1 
4.1.3.1 GS inhibitors activate mTOR in a dose dependent 
manner 
Due to the importance of mTOR in cell growth and protein synthesis 
regulation it is not surprising that a large amount of studies and papers are 
focused on understanding how the kinase senses amino acids. A recent 
paper [152] confirmed the paradoxical observation that we made while 
studying the effects of Gln depletion on hepatocellular carcinoma cell lines 
[136]: the irreversible Glutamine Synthetase (GS) inhibitor, methionine-L-
sulfoximine (MSO), while further depleted cell Gln, stimulated mTOR.  
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To discriminate if the GS inhibitor was directly involved in the kinase 
activation, HepG2 cells were treated for 6 hours with MSO or with another 
GS inhibitor, DL-phosphinothricin (PPT), in the absence of Gln. As shown 
in Fig. 29, both MSO and PPT were able to activate mTOR in a dose-
dependent manner.  
 
  
Fig. 29 MSO and PPT stimulated mTOR in Gln deprived cells. Western 
Blot of p70S6K1 (phospho T389 and T421/S424), p85S6K1 (phospho T412 
and T444/S447) was performed in HepG2 cells incubated for 6 hours in 
DMEM without Gln in the presence of increasing concentration (1, 2, 4 mM) 
of MSO or PPT. Control cells were maintained in presence of 4 mM Gln (+). 
Total S6K1 was used as a loading control. The experiment was repeated 
three times with comparable results. 
 
The phosphorylated fraction of S6K1 was even higher when PPT (4 mM) 
was added instead of Gln (4 mM) (Fig. 29). Furthermore PPT (4 mM) was 
also able to further activate mTOR in Gln fed cells, while MSO did not show 
any supra-stimulatory effects in the presence of extracellular Gln (Fig. 30). 
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Fig. 30 PPT stimulated mTOR in Gln fed cells. Western Blot of S6K1 
(phospho T389 and T412) was performed in HepG2 cells incubated for 6 
hours in DMEM in the presence of 4 mM Gln and/or 4 mM MSO or 4mM 
PPT. S6K1 total was used as a loading control. The experiment was 
repeated three times with comparable results. 
 
The functional consequences of mTOR activation were directly investigated 
measuring the rate of protein synthesis. MSO and PPT did not produce any 
changes in protein synthesis, when added in presence of Gln (Fig. 31); 
however protein synthesis rate was significantly hindered by Gln starvation 
and GS inhibitors caused a further decrease of Leu incorporation, 
suggesting that, despite mTOR activation, cell Gln availability was further 
decreased in the presence of GS inhibitors.  
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Fig. 31 MSO and PPT affected protein synthesis rate in Gln starved 
cells. HepG2 cells incubated for 6 hours in DMEM with or without 4 mM 
Gln alone or in combination with 4 mM MSO or 4mM PPT. Protein 
synthesis rate was measured as described in Methods. A single 
representative experiment is shown. * p<0.05 vs. Gln fed cells, § p<0.05 vs. 
Gln starved cells. 
 
4.1.3.2 MSO prevents mTOR inactivation caused by Gln and 
EAA depletion 
To asses if GS inhibitors synergized with essential amino acids (EAA) to 
stimulate mTOR, HepG2 cells were incubated in an unsupplemented saline 
solution (EBSS) for 6 hours, in the absence or in the presence of Gln and 
EAA (for control) or of MSO or PPT alone or in combination with EAA. 
When added alone, MSO produced an increase in phosphorylation of 
S6K1, which was further raised by adding EAA simultaneously (Fig. 32).  
Instead, while PPT alone was not able to prevent the dephosphorylation of 
S6K1, a powerful mTOR activation was detected upon EAA 
supplementation, reaching control levels (Gln + EAA).  
 
 - 91 - 
 
Fig. 32 MSO prevented mTOR inactivation. Western Blot of p70S6K1 
(phospho T389 and T421/S424), p85S6K1 (phospho T412 and T444/S447) 
was performed in HepG2 cells incubated for 6 hours in EBSS 
supplemented with the indicated compounds, alone or in combination: Gln 
(4 mM), EAA (1x, at the concentration present in DMEM), MSO (4 mM), 
PPT (4 mM). Total S6K1 was used as a loading control. The experiment 
was repeated three times with comparable results. 
 
Given the amino acidic structure of MSO and PPT (see Fig. 8), it was 
possible to verify their uptake by HPLC. Amino acid analysis revealed that 
MSO cell content was higher when added alone then when combined with 
EAA (Fig. 33), suggesting a competition in membrane transport. Instead, 
PPT content was higher when combined with EAA (Fig. 33) rather than 
given alone, suggesting that the higher effect on S6K1 phosphorylation 
may be due not only to the presence of EAA, since cell EAA were 
comparable to those measured in cells treated with MSO and EAA (not 
shown, see [153]), but to the increased amount of PPT.  
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Fig. 33 PPT and MSO uptake. Amino acids content was determined as 
described in HepG2 cells. The incubation medium was EBSS for 6 hours 
with or without Gln, MSO, PPT (all at 4 mM), Essential Amino Acids (EAA, 
at the concentration present in DMEM). 
 
Although it is not possible to identify the amino acid sensor upstream of 
mTOR, from these results, two important observations have emerged.  
First, Gln is not only involved in Leu uptake but it really seems to have a 
direct effect on mTOR stimulation. Furthermore, the relationship between 
Gln and Leu uptake seems to be more complex than previously proposed 
[45]. It should be stressed that, if Gln activates mTOR, mTOR activation is 
known to promote Gln metabolism [47]. 
Second, two GS inhibitors, the non-proteinogenic amino acids MSO and 
PPT, besides further depleting cell Gln, activate mTOR. It has been 
proposed that this effect should be referable to the inhibition of GS activity 
[152, 154]; however considering the dose dependence and the affinity of 
GS for MSO and PPT [155], it is more likely that these two amino acids 
deceive sensors upstream of mTOR mimicking Gln and/ or Leu. 
Interestingly, MSO and PPT together were able, in the absence of Gln and 
EAA, to fully activate mTOR (data not shown). Hence, they could be 
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considered useful tools for assessing how amino acids are sensed by 
mTOR. 
Thus, it is possible to conclude that not only EAA stimulate mTOR; 
however, further studies are needed to understand the basis of this 
activation, which is also involved in supporting uncontrolled cell growth in 
several cancer models. 
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4.2 Glutamine depletion is a potential therapeutic tool 
against selected types of cancer  
Metabolic rewiring is now effectively considered a hallmark of cancer [1]. 
The metabolic relevance of Gln and the effects of Gln depletion are still 
objects of several studies. As described in Introduction (see 1.1.2 
“Glutamine Addiction”: a new concept in cancer metabolism) Gln is the 
most abundant amino acid in serum and it is involved is several roles: 
nucleotides and protein synthesis, essential amino acids uptake (as 
described above), synthesis of other non essential amino acids (i.e. 
glutamate, asparagine, serine, praline). Moreover Gln is used as an 
anaplerotic substrate in different kind of cancers to fuel cell growth [35]. For 
this reason, targeting glutamine metabolism may prove a useful tool for 
cancer control. 
 
4.2.1 “GS positive” human hepatocellular carcinoma (HCC) cell 
lines are sensitive to glutamine starvation 
Gln is synthesized from glutamate and ammonium through the enzyme 
Glutamine Synthetase (GS). GS activity is regulated at both transcriptional 
and post-transcriptional levels [52, 53]. However, it has been demonstrated 
that the expression of GLUL, the gene coding for GS, is under β-catenin 
control. β-catenin, a cytoskeleton protein, when mutated, may act as a 
monogenic transcription factor in several human tumors and, in particular, 
in HCC. Therefore, the effects of Gln depletion, obtained with the antitumor 
glutamine-depleting enzyme L-asparaginase (ASNase), from E. 
chrysanthemi, alone or in combination with the irreversible GS inhibitor 
(MSO), were evaluated on HCC cell lines, both in vitro and in vivo. 
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4.2.1.1 Glutamine starvation affects human HCC cell viability  
4.2.1.1.1 ASNase depletes cell glutamine and inactivates mTOR 
The β-catenin mutated HepG2 cell line and the β-catenin wild type Huh7 
cell line were incubated in the presence of ASNase (1 U/ml) with or without 
1 mM MSO for 24 hours. Amino acid analysis revealed that ASNase 
caused a clear cut decrease in Gln content in both cell lines, while MSO 
presence during ASNase treatment caused a further decrease of Gln 
content which fell under analytical detection limits (< 1 nmol). Moreover 
HepG2 cells showed higher Gln content compared to Huh7 and 
accumulated more GS inhibitor (Fig. 34). We have indeed demonstrated 
that MSO uptake is mediated by system A transport [136] which is more 
expressed in HepG2 cells (not shown).  
As a consequence of the intracellular Gln decrease caused by ASNase 
treatment, mTOR activity, evaluated from the phosphorylated status of 
S6K1, was severely decreased 6 hours after treatment in HepG2 cells and, 
at later times, in Huh7.  
One of the consequences of the nutritional stress caused by amino acid 
shortage, is the phosphorylation, at residue S51, of the eukaryotic initiation 
translation factor 2α (eIF2α) [156] operated by the general control non 
repressed 2 (GCN2), a serine/threonine kinase that senses amino acid 
deficiency through binding to uncharged tRNA. Consistently, in ASNase 
treated cells it was observed an increase in the phosphorylated fraction of 
eIF2α, more evident in HepG2 cells (Fig. 35). However, MSO caused 
paradoxical effect not only in mTOR activation (see 4.1.3 Glutamine 
Synthetase inhibitors activate mTORC1) but also in the inactivation of 
eIF2α (Fig. 35), confirming the hypothesis that it deceives cellular amino 
acid sensors.  
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Fig. 34 ASNase lowered Gln intracellular content in HCC cells. Amino 
acid content was determined as described in HepG2 (A) and Huh7 (B) cells 
incubated for 24 hours in DMEM supplemented with 1 U/ml ASNase (A) or 
1 U/ml ASNase with 1 mM MSO (AM). A single representative experiment 
is shown.  
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Fig. 35 ASNase lowered mTOR activity and caused the 
phosphorylation of eIF2α. Western Blot of p70S6K1 (phospho T389 and 
T421/S424), eIF2α (phospho S51) was performed in HepG2 and Huh7cells 
incubated, for the indicated times, in DMEM with 1 U/ml ASNase (A) or 1 
U/ml ASNase with 1 mM MSO (AM). β-tubulin was used as a loading 
control. The experiment was repeated three times with comparable results. 
 
4.2.1.1.2 β-catenin-mutated HepG2 and Huh6 cell lines are extremely 
sensitive to Gln starvation. 
β-catenin-mutated HepG2 (HCC) and Huh6 (HB) cells and β-catenin wild 
type Huh7 (HCC) cells were incubated in DMEM for 72 hours with 
decreasing Gln concentrations. Cell count revealed that β-catenin mutated 
cells were more dependent on the extracellular Gln concentration than 
Huh7 (Fig. 36). 
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Fig. 36 β-catenin-mutated cell number was affected by Gln shortage. 
HepG2, Huh6 and Huh7 cells were incubated in DMEM supplemented with 
10% dialyzed FBS and the indicated concentrations of Gln. After 72 hours, 
cells were rinsed and counted. Data are expressed in % of each control (4 
mM fed cells). Means of five determinations ± SD are shown. 
 
Then, HepG2, Huh6 and Huh7 cells were incubated with ASNase, ASNase 
and MSO or MSO alone. Cell count confirmed the higher sensitivity of β-
catenin mutated cells to Gln starvation, obtained with ASNase. 
Furthermore, the incubation in the presence of both ASNase and the GS 
inhibitor caused a dramatic fall in the cell number of β-catenin-mutated cell 
population (Fig. 37 and Fig. 38). Also Huh7 cell population was affected 
when MSO was added to the glutamine-depleting enzyme. However MSO 
alone, in vitro, had no effect in all the cell lines tested (Fig. 37), suggesting 
that GS activity is critical only during Gln deprivation. Nevertheless, since 
MSO competes with Gln for system A transport, it cannot be excluded that 
in the presence of 4 mM Gln, MSO uptake could be partially inhibited.  
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Fig. 37 ASNase severely affected β-catenin-mutated cell population. 
HepG2, Huh6 and Huh7 cells were incubated in DMEM in the presence of 
ASNase (1 U/ml) or MSO (1 mM) or with the two compounds together. 
Control cells were incubated in standard growth medium. After 72 hours, 
cells were counted. Data are expressed in % of each control (4mM fed 
cells). Means of five determinations ± SD are shown. 
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Fig. 38 ASNase severely affected β-catenin-mutated cell population. 
HepG2, Huh6 and Huh7 cells were incubated in DMEM in the presence of 
ASNase (1 U/ml) or MSO (1 mM) or with the two compounds together. 
Control cells were incubated in standard growth medium. After 72 hours, 
cells were photographed. Single representative fields of each condition are 
shown, 100x. 
 
Furthermore, it should be noticed that the effect of ASNase, compared with 
that obtained just incubating cells in the absence of extracellular Gln, was 
higher; indeed, in HepG2 cells ASNase caused a 65% cell loss while the 
incubation in the absence of Gln caused only a 52% loss of cell population. 
It is likely that the ASNase treatment is more severe since the enzyme 
maintains a very high transmembrane gradient of Gln thus causing a fast 
efflux of the amino acid from the intracellular compartment.  
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4.2.1.1.3 In HepG2 cells Gln is utilized as an anaplerotic substrate.  
Gln can enter Krebs cycle through a first deamidation operated by 
glutaminase (GLS1 and GLS2); subsequent deamination by glutamate 
dehydrogenase (GDH) or transamination, eventually produces the α-
ketoglutaric acid (αKG, 2-oxo-glutarate) from Gln. In HepG2 cells, but not in 
Huh7 cells, other anaplerotic substrates, such as pyruvate and αKG, 
mitigate ASNase effects (Fig. 39), confirming that Gln fuel Krebs cycle in 
this model.  
Consistently with these data, it was observed by another research group 
that HepG2 cells utilize Gln as predominant anaplerotic precursor [157], 
confirming that HepG2 cells is effectively a “glutamine addicted” model. 
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Fig. 39 Pyruvate and αKG mitigated ASNase antiproliferative effects. 
HepG2 and Huh7 cells were incubated in DMEM (pyruvate-free) with 
ASNase (1 U/ml) and ASNase + MSO (1 mM) in the absence or in the 
presence of pyruvate (1 mM) and/or dimethyl α-ketoglutaric acid (αKG, 8 
mM). Data are expressed as % of control (cells incubated in standard 
growth medium). Means of two experiments with four determinations each, 
± SD are shown. * p < 0.05 compared with ASNase-treated cells. 
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4.2.1.1.4 Notch pathways are not involved in ASNase sensitivity  
Notch and β-catenin pathways are known to overlap often. It has been 
demonstrated that in some kind of cancers (i.e. colon cancer), the 
membrane bound Notch physically associates with the active 
(unphosphorylated) form of β-catenin, reducing the WNT/ β-catenin signal 
independent of GS3Kβ activity [158]. Conversely, it has also been proven 
that in colorectal cancers, exhibiting an uncontrolled β-catenin due to APC 
mutations, a downstream Notch activation occurs. This activation is due to 
a β-catenin-dependent overexpression of the Notch ligand Jagged 1 [159]. 
Taking into account the interaction between Notch and β-catenin pathways 
and the fact that many HCC cells do express Notch, which is, in addition, 
correlated to a poor prognosis [160], we evaluated the effects of Notch 
inhibition in our models. Since Notch activation is mediated by γ-secretase, 
HCC cells were incubated with DAPT, a γ-secretase inhibitor, in the 
absence or in the presence of ASNase (1 U/ml).  
Cell count revealed that not all the cell lines were sensitive to DAPT, with a 
maximal anti-proliferative effect of 20% at the highest DAPT dose (75 μM) 
obtained in HepG2 cells (Fig. 40). Moreover no effect of DAPT was 
observed in ASNase treated Huh6 cells and only a partial addition of the 
highest dose (75 μM) of DAPT with ASNase was observed in HepG2 cells 
(Fig. 40). In Huh7 cells ASNase did not affect cell proliferation and DAPT 
effects were similar in ASNase-treated and untreated cells (Fig. 40). 
However, measuring in parallel experiments the mRNA abundance of HES-
1, a direct Notch target, it was evident that in all the cell lines an inhibition 
of Notch had effectively occurred (Fig. 41). HES-1 decrease was higher in 
HepG2 cells, consistent with the larger effects of the γ-secretase inhibitor 
on cell proliferation in this cell line.  
Moreover the expression of c-myc, another downstream target of Notch, 
was evaluated. Unlike HES-1, c-myc behaved differently depending on cell 
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type. In fact, c-myc expression in Huh7 cells did not change, in HepG2 
halved, and in Huh6 almost doubled (Fig. 42).  
This behaviour does not negate the effects of Notch inhibition, since c-myc 
is also a direct β-catenin target. So, considering the complex mutual 
relationship linking these oncogenic signals [158, 159], it is possible that, as 
a consequence of Notch inhibition, changes in β-catenin status may occur.  
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Fig. 40 Notch inhibitors did not synergize ASNase. HepG2, Huh6 and 
Huh7 cells were incubated in DMEM in presence of the indicated 
concentrations of DAPT in the absence or in the presence of ASNase (1 
U/ml). Control cells were incubated in standard growth medium. After 72 
hours, cells were counted. Data are expressed in % of the corresponding 
control. Means of three experiments with six determinations each ± SD are 
shown. * p< 0.05 vs. control cell, § p< 0.05 vs. ASNase-treated cells. 
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Fig. 41 DAPT lowered HES-1 expression. HES-1 expression was 
analyzed by RT-qPCR. HepG2, Huh6 and Huh7 cells were incubated in 
DMEM with DAPT (+, 75 μM) or in standard growth medium (-). Relative 
HES-1 mRNA abundance was normalized to RPL-15 and expressed as 
Arbitrary Units. 
 
 
 
 
 
 
 - 107 - 
 
Fig. 42 c-myc expression showed different dependency on DAPT 
depending on the cell model. HepG2, Huh6 and Huh7 cells were 
incubated in DMEM with DAPT (75 μM) or in standard growth medium (-). 
Relative c-myc mRNA abundance was normalized to RPL-15 and 
expressed as Arbitrary Units. 
 
4.2.1.1.5 β-catenin silencing mitigates ASNase effects 
Given that Notch inhibition did not modify ASNase effects on all the cell 
lines tested (see above), a direct involvement of this pathways on 
“glutamine addicted” cancer phenotype is unlikely. Furthermore it is known 
that β-catenin controls the expression of GS and c-myc, which in turn 
regulates the expression of GLS1 [75]. Thus, two key enzymes of Gln 
metabolism seems to be under direct or indirect β-catenin control, 
suggesting a straight involvement of this oncogene in leading to a 
“glutamine addicted” HCC.  
To confirm this hypothesis, the effects of ASNase were evaluated on β-
catenin- silenced HepG2 and Huh6 cells. The silencing procedure 
determined a clear cut fall in β-catenin (CTNNB1) mRNA content (> 70%) 
in both cells lines (Fig. 43). Furthermore, compared with scramble-
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transfected cells, β-catenin was still heavily down-regulated 6 days after 
transfection in CTNNB1-silenced cells (Fig. 43).  
 
 
Fig. 43 β-catenin was still down-regulated 6 days after gene silencing. 
CTNNB1expression was analyzed by RT-qPCR in HepG2 and Huh6 cells 2 
days after transfection (upper). Relative CTNNB1 mRNA abundance was 
normalized to RPL-15 and expressed as Arbitrary Units. β-catenin protein 
expression was evaluated by Western blot in parallel cultures 6 days after 
transfection (bottom). β-tubulin was used as a loading control. For PCR 
means of four different experiments with SD are shown. *p < 0.05. For 
Western blot, a representative experiment of three is shown. 
  
To verify that the silencing procedure reduced not only β-catenin protein 
levels but also its activity, the expression of the β-catenin downstream 
targets, cyclin D1 (CCND1) and c-myc, was monitored. In addition, the c-
myc-downstream target GLS1 was also evaluated. As shown in Fig. 44, 
both cyclin D1 and c-myc expression decreased (60% and 40% 
respectively). Moreover also the c-myc downstream target GLS1 mRNA 
expression decreased (about 30%), strengthening the link between β-
catenin and Gln metabolism.  
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Fig. 44 β-catenin downstream target expression was lowered in 
silenced cells. CCND1 (A), c-MYC (B) and GLS1 (C) expression in HepG2 
silenced cells was analyzed by RT-qPCR. Relative CCND1 (A), c-MYC (B) 
and GLS1 (C) mRNA abundance was normalized to RPL-15 and expressed 
as Arbitrary Units. Data are means ± SD of three independent experiments.  
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Fig. 45 ASNase did not affect β-catenin-silenced cell viability. 3 days 
after transfection, scramble- (Scr) and β-catenin- (Si-β-cat) silenced HepG2 
and Huh6 cells were incubated in the absence or in the presence of 
ASNase (1 U/ml). After 72 hours cells were counted. Data represent the 
means ± SD of three independent experiments whit four determinations 
each. * p< 0.05; ns, not significant.  
 
In β-catenin silenced cells, a 3-day treatment with ASNase (from day 3 to 
day 6 after transfection) significantly lowered the number of HepG2 and 
Huh-6 cells transfected with scrambled siRNA but had no significant effect 
in β-catenin-silenced cells (Fig. 45). However, it should be also noticed that 
β-catenin downregulation itself severely hindered cell proliferation.  
These data support the involvement of β-catenin in the enhanced sensitivity 
to ASNase of HCC mutated cell lines.  
 
4.2.1.1.6 Glutamine availability seems to influence β-catenin activity 
We have demonstrated that β-catenin influences Gln metabolism, yet it is 
unknown if, conversely, Gln availability may influence β-catenin activity.  
ASNase effects on β-catenin activity were assessed with the TOPflash 
reporter assay, which is a direct and reliable measure of the β-catenin/Tcf-
dependent transcriptional activity [161]. 
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In ASNase-treated Huh6 cells, a significant increase of luciferase activity 
was observed (Fig. 46). Also in HepG2 cells a slight increase of the 
reporter activity occurred in the same experimental condition but it did not 
reach a statistical significance. Interestingly the luciferase activity was 20-
fold higher in HepG2 cells than in Huh6 (Fig. 46), suggesting that in the 
former cell model the deletion of exon-3 of CTNNB1 gene leads to a more 
active β-catenin than the point mutated CTNNB1 gene of the latter.  
 
 
Fig. 46 ASNase increased luciferase activity in Huh6 cells. HepG2 and 
Huh6 cells were incubated in presence of ASNase (1 U/ml) or in standard 
growth medium for control. After 6 hours cells were transfected with both 
Firefly luciferase, under the control of a TCF enhancer, and Renilla 
luciferase, used as internal control for transfection efficiency. After 24 
hours, luciferase assay was performed. Data are expressed as relative 
Firefly/Renilla luciferase activity. Results are mean ± SD of two 
independent experiments with two determination each. § p<0.05 referred to 
control; * p<0.05 compared to HepG2 control luciferase activity.  
 
However, the same experiment performed in Gln-deprived cells yielded 
inconsistent results. It should be noted that, since ASNase and Gln 
deprivation causes a strong nutritional stress, followed by protein synthesis 
attenuation and loss in cell viability it cannot be excluded that the effects of 
the treatments on luciferase activity might be confused by different 
translational rates.  
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In conclusion, ASNase caused a clear cut decrease of Gln intracellular 
content in all the cell lines tested, which, in turn, determined a decrease in 
mTOR activity and the phosphorylation of eIF2α. This condition affected the 
viability of β-catenin-mutated HCC and HB cell lines, but not that of β-
catenin wild type Huh7 HCC line. MSO alone, which in vitro did not produce 
changes either in Gln content (not shown, see [136]) or in cell proliferation 
rate, further depleted cell Gln by inhibiting GS activity (see [136]) and 
deceived amino acid sensors. This condition led to a marked cell viability 
loss in all the cell lines tested, even in the ASNase-resistant line. 
Anaplerotic substrates mitigated ASNase effects in the β-catenin mutated 
HepG2 cell line, suggesting that mutated β-catenin leads to a Gln-addicted 
phenotype. This hypothesis is strengthened by two observations:  
1. β-catenin-silenced HepG2 and Huh6 cells no longer responded to 
ASNase;  
2. the inhibition of other pathways (at least Notch) did not produce any 
changes in the cell response to ASNase.  
These results prompted us to evaluate the effects of Gln depletion on HCC 
xenografts models. 
 
4.2.1.2 ASNase and MSO affect the growth of HCC xenografts 
4.2.1.2.2 ASNase and MSO treatment is well tolerated 
Before establish HCC xenografts, the toxicity of the combined treatment 
with ASNase (5 U/g) and MSO (10 mg/kg) was assessed in nude mice.  
The combined treatment, administered three times a week for three weeks, 
was well tolerated by athymic nude mice, with no significant alteration in 
body and liver weights (Fig. 47 A, B).  
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Fig. 47 ASNase and MSO was not toxic for nude mice. Male athymic 
nude mice were treated by intraperitoneal (i.p.) injection of ASNase and 
MSO three times a week for three weeks. At the end, body (A) and liver 
weight (B) were determined. Data represent means ± SD of a single 
experiment with three mice for each group.This experiment was performed 
at LIGeMa by the group of Prof. Arcangeli. 
 
To evaluate the biochemical effect of the treatment, serum and liver amino 
acids were determined in control and treated mice. In serum, major 
changes were observed for asparagine (Asn) and Gln, which disappeared 
in the serum of treated animals, whereas aspartate (Asp) and glutamate 
(Glu) levels markedly increased (Fig. 48). MSO was also detected.  
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Fig. 48 ASNase and MSO depleted serum Gln in mice. Male athymic 
nude mice were treated with ASNase and MSO for three weeks. At 
sacrifice, peripheral blood was collected, serum extracted and amino acid 
content analyzed by HPLC. A representative experiment is shown.  
  
Moreover ASNase and MSO treatment caused a significant decrease in 
liver Gln content; in liver homogenates of treated animals a small amount of 
MSO was detected (Fig. 49 A), demonstrating the tissue uptake of the 
inhibitor. Consistently, the activity of Glutamine Synthetase (GS), 
determined in parallel in the same samples, was lowered by more than 
97% in treated animals compared with control (Fig. 49 B).  
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Fig. 49 MSO entered liver and inhibited liver GS. Male athymic nude 
mice were treated with intraperitoneal (i.p.) injections of ASNase and MSO. 
At sacrifice, liver was explanted and analyzed. A. Amino acid content was 
analyzed by HPLC. Means (n=3) ± SD are shown. * p<0.05 B. Liver GS 
activity was measured as described in Methods. Means (n=3) ± SD are 
shown. ***p<0.001. 
 
4.2.1.2.2 ASNase and MSO treatment suppresses HepG2 xenografts. 
2.5 million cells were subcutaneously (s.c.) injected in athymic nude mice. 
After 8 days, tumors were palpable and treatment started. Five mice per 
group (four for MSO group) were treated with ASNase or MSO, with both 
drugs together or with vehicle for control.  
After 19 days of treatment, at sacrifice, the growth of HepG2 xenografts 
resulted suppressed in mice undergone the combined treatment, while it 
was significantly hindered (by 51% and 60%, respectively) in animals 
treated with ASNase or MSO alone. Consistently, the weight of the 
explanted masses was significantly lower in animals treated with ASNase 
or MSO alone (34% and 61% respectively), while no tumor mass was 
dissectable in animals treated with ASNase and MSO together (Fig. 51). 
The effects of the different treatments on tumor growth were consistent with 
the macroscopic inspection of the xenografted animals (Fig. 52).  
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As shown in the picture, both single treatments caused a variable effect on 
tumor growth, while no mass can be noticed in mice receiving the 
combined treatment ASNase and MSO.  
From histological evaluation, it was observed that, while β-catenin showed 
a normal membrane positivity in livers of mice, the protein signal was 
diffused and mainly into the nucleus in xenografts (Fig. 53), a clear 
indicator of its activated status.  
Furthermore, HepG2 tumors were also positive for GS (Fig. 54 upper, top 
left) and the expression of the enzyme was appreciably increased by 
neither ASNase (Fig. 54, upper, top right) nor MSO (Fig. 54, upper, bottom 
left); no GS-positive cell was detected from animals treated with ASNase 
and MSO (Fig. 54, upper, bottom right) in tissue samples deriving from 
xenograft injection site. GS expression in the liver (Fig. 54, bottom) had the 
typical perivenous pattern of expression and was induced by ASNase, 
MSO or ASNase and MSO, with an extension of the expression to several 
rows of hepatocytes.  
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Fig. 50 ASNase and MSO suppressed HepG2 tumor growth. 8 days 
after HepG2 s.c. injection mice were treated i.p. with ASNase (5 U/g) or 
MSO (10 mg/kg), alone or together, or with vehicle, 3 times a week for 19 
days. Tumor growth was measured with caliper. Means ± SD is shown 
(n=5, n=4 for MSO group). * p < 0.05; *** p < 0.001 assessed with two-tail 
Student’s t test for unpaired data. This experiment was performed at 
LIGeMa by the group of Prof. Arcangeli. 
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Fig. 51 No tumor was found in ASNase and MSO treated mice. 8 days 
after HepG2 s.c. injection mice were treated i.p. with ASNase (5 U/g) or 
MSO (10 mg/kg), alone or together, or with vehicle three times a week for 
19 days. At the end, tumors were dissected and weighted. Means ± SD are 
shown (n=5, n=4 for MSO group). This experiment was performed at 
LIGeMa by the group of Prof. Arcangeli. 
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Fig. 52 HepG2 xenografts in mice. Eight days after HepG2 s.c. injection 
mice were treated i.p. with ASNase (5 U/g) or MSO (10 mg/kg), alone or 
together, or with vehicle three times a week for 19 days. At the end, 
animals were anesthetized and photographed. This experiment was 
performed at LIGeMa by the group of Prof. Arcangeli. 
 
 
  
Fig. 53 β-catenin signal was diffuse in tumors. Histochemical analysis of 
β-catenin expression in liver and HepG2 xenografts. A single representative 
field is shown, x40. This analysis was performed by the group of Prof. Silini. 
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Fig. 54 GS was induced in liver 
of treated mice. Histochemical 
analysis of Glutamine Synthetase 
(GS) expression in HepG2 
xenografts (upper) and in liver 
(bottom). A single representative 
field for each condition is shown, 
x40. This analysis was performed 
by the group of Prof. Silini.  
 
 
 
 
 
 
 
 
 
 
 
 
 
From a biochemical point of view, both ASNase and ASNase and MSO 
treatment caused a marked depletion of Asn and Gln in serum with a 
consisted increase of Asp and Glu. MSO was detected in mice treated with 
ASNase and MSO or MSO alone (Fig. 55 A). The decrease of Asn and Gln 
in serum was also detected in tumor tissue of ASNase treated mice (Fig. 55 
B). However, in these samples a fall in Glu content was also detected (Fig. 
55 B), pointing to an attempt to synthesize de novo Gln through GS. For 
ASNase and MSO treated mice, no tumor was dissected, and it was not 
possible to evaluate amino acids.  
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Fig. 55 ASNase lowered serum and tumor Asn and Gln content. Eight 
days after HepG2 s.c. injection mice were treated i.p. with ASNase (5 U/g) 
or MSO (10 mg/kg), alone or together, or with vehicle three times a week 
for 19 days. At the end, amino acids were extracted as described in 
Methods and analyzed by HPLC. Means ± SD are shown (n= 5, n=4 for 
MSO group). *p<0.05; *** p<0.001 
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4.2.1.2.3 The combined treatment ASNase and MSO is effective also in 
Huh7 xenografts.  
To understand if the sensibility to the combined (ASNase and MSO) 
treatment was limited to β-catenin-mutated tumors, athymic nude mice 
were s.c. injected with HepG2 and Huh7 cells on each flank. After 2 weeks, 
both tumors were palpable and treatment started. After 3 weeks, a massive 
effect of the treatment on HepG2 xenografts was observed, confirming 
what previously demonstrated. However also Huh7 tumor growth was 
significantly impaired by the treatment (Fig. 56).  
Determination of tumor volumes at sacrifice confirmed a marked inhibition 
of cancer cell growth in both HepG2 (- 91%) and Huh7 xenografts (- 46%), 
as shown in Fig. 57. 
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Fig. 56 The combined treatment (ASNase and MSO) is effective also in 
Huh7 xenografts. HepG2 and Huh7 were simultaneously s.c. injected on 
the left and right flank of animals. After 2 weeks mice were treated i.p. with 
ASNase (5 U/g) and MSO (10 mg/kg) or with vehicle for control three times 
a week for three weeks. Tumor growth was monitored with caliper. Means ± 
SD are shown (n=3 each group). *p<0.05, assessed with two-tail Student’s 
t test for unpaired data. This experiment was performed at LIGeMa by the 
group of Prof. Arcangeli. 
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Fig. 57 The combined treatment affected Huh7 tumors. HepG2 and 
Huh7 cells were simultaneously s.c. injected on the left and right flank of 
nude mice. After 2 weeks, mice were treated i.p. with ASNase (5 U/ml) and 
MSO (10 mg/kg), or with vehicle for control, three times a week for three 
weeks. At the end, masses were dissected and weighted. Means ± SD are 
shown (n=3). *p<0.05. This experiment was performed at LIGeMa by the 
group of Prof. Arcangeli. 
 
From these results, it is evident that depleting extracellular Gln (with 
ASNase) and inhibiting de novo Gln synthesis (with MSO) significantly 
affected HCC tumor growth. Yet, given the limited number of mice used (3 
for each group) in this experiment, it has not been possible to evaluate if 
significant differences exist in the sensitivity of the two xenografts to the 
combined treatment.  
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4.2.1.3 β-catenin mutated HC-AFW1 cell line is ASNase-resistant 
in vitro but ASNase-sensitive in vivo. 
4.2.1.3.1 HC-AFW1 cells over-express GS and resist to ASNase treatment  
β-catenin-mutated paediatric HC-AFW1 HCC cells showed the classical 
nuclear localization of β-catenin, as demonstrated with 
immunofluorescence (Fig. 58). However, unlike HepG2 and Huh6 ASNase-
sensitive cells, the viability of this model was not affected by ASNase alone 
(Fig. 59 and Fig. 60). In fact, only the combined treatment was able to 
severely hinder HC-AFW1 growth (Fig. 59 and Fig. 60).  
 
 
Fig. 58 β-catenin localization. Merged immunofluorescence of β-catenin 
in HC-AFW1, HepG2 and Huh6. Nuclei, red; β-catenin, green. A single 
confocal section is shown. 
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Fig. 59 HC-AFW1 cells were not affected by ASNase in vitro. HC-
AFW1, Huh6, and HepG2 cells were incubated in DMEM in the presence of 
ASNase (1 U/ml), with or without MSO (1 mM), or with MSO (1 mM) alone. 
Control cells were incubated in standard growth medium. After 72 hours, 
cells were counted. Data are expressed in % of the corresponding control, 
maintained in growth medium with 4 mM Gln. Means of two experiments 
with five independent determinations each ± SD are shown. *p < 0.05 
compared with control; § p < 0.05 compared with ASNase treated cells; ns, 
not significant. 
 
 
 
Fig. 60 HC-AFW1 cells were not affected by ASNase. HC-AFW1cells 
were incubated in DMEM in the presence of ASNase (1 U/ml) with or 
without MSO (1 mM). Control cells were incubated in standard growth 
medium. After 72 hours, cells were photographed. Magnification 100x. 
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HC-AFW1 cells expressed the highest level of GS, both at mRNA and 
protein level (Fig. 61, Fig. 62), compared with Huh6 and HepG2 cells. 
Furthermore HC-AFW1 cells showed lower levels of asparagine synthetase 
(ASNS) and of SLC38A2 and SLC1A5 (for the SNAT2 and ASCT2 
transporters, Fig. 61) mRNAs compared with HepG2. 
ASNase treatment decreased mTOR activity only in HepG2 and Huh6 cells, 
while it did not affected kinase activity in HC-AFW1 (Fig. 62), suggesting 
that a not completely fall of Gln intracellular content occurred in this cell 
model. The activation of mTOR in ASNase and MSO treated cells was not 
surprising (see paragraph 4.1.3 Glutamine Synthetase inhibitors activate 
mTORC1). GS protein abundance, which is regulated also by Gln 
availability [52, 53], clearly rose in HepG2 and Huh6 cells after 6 hours of 
ASNase treatment and, even further, after 24 hours, but in HC-AFW1 cells 
a slight increase was detected only 24 hours after ASNase administration.  
Consistently, amino acid analysis revealed that, while in HepG2 and Huh6 
cells ASNase completely depleted cell Gln, in HC-AFW1 cells intracellular 
Gln was still detectable (30% compared to control values) after 24 hours of 
ASNase treatment (Fig. 63).  
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Fig. 61 HC-AFW1 cells expressed higher GLUL levels. GLUL, ASNS, 
SLC38A2, and SLC1A5 expression levels were analyzed by RT-qPCR. 
Cells were incubated in standard growth medium. Relative gene mRNA 
abundances were normalized to RPL-15 and expressed as Arbitrary Units. 
  
 
 
Fig. 62 ASNase did not inactivate mTOR in HC-AFW1 cells. Western 
Blot of S6K1 (phospho T389), ASNS, and GS was performed in Huh6, HC-
AFW1, and HepG2 cells incubated, for the indicated times, in DMEM with 1 
U/ml ASNase (A) or 1 U/ml ASNase with 1 mM MSO (AM). GAPDH was 
used as a loading control. The experiment was repeated three times with 
comparable results. 
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Fig. 63 ASNase did not completely deplete HC-AFW1 cell Gln. Amino 
acid content was determined, as described in Methods, in Huh6, HC-
AFW1, and HepG2 cells incubated for 24 hours in DMEM with 1U/ml 
ASNase or in standard growth medium for control. A single representative 
experiment is shown.  
  
This result is consistent with the behaviour of mTOR and GS described 
above and may be caused by the low expression of the exchange 
transporter ASCT2, which limits Gln efflux, and the high expression of GS, 
which refills cell Gln. In fact, adding the GS inhibitor, MSO, to ASNase 
completely depleted intracellular Gln also in HC-AFW1 cells (not shown), 
thus leading to a severe decrease in cell viability (see above). 
Moreover, HC-AFW1 expressed very low levels of ASNS, which increased 
after ASNase treatment. This observation contradicts the hypothesis that 
low asparagine synthetase levels are symptoms of ASNase sensitivity as 
recently proposed for HCC [162], and strengthens the idea that the 
metabolic stress caused by ASNase is more dependent on intracellular Gln 
content and Gln-related enzymes levels. However, ASNase resistance is 
more likely a multifactor phenomenon [163], possibly due to different 
mechanisms in different biological models.  
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4.2.1.3.2 HC-AFW1 ASNase resistant model is sensitive to the combined 
(ASNase and MSO) treatment in vivo.  
HC-AFW1 cells were s.c. injected in NGS mice. After 2 weeks animals 
were treated with ASNase (5 U/g) and MSO (10 mg/kg), with either drug 
alone, or with vehicle for control. After 10 days animals were sacrificed and 
tumor masses were dissected and weighted. At explantation time, only the 
combined treatment with ASNase and MSO produced a significant 
decrease (60%) in the mean weight of tumors at sacrifice, while the mean 
weight of tumors in mice treated with ASNase or MSO was smaller than 
control without reaching statistical significance (Fig. 64 and 65). However, 
when the starting tumor volume was considered, all treatments caused a 
significant delay in tumor growth in terms of relative volume increase (Fig. 
66). Furthermore, the Ki67 index, an indicator of proliferative activity of the 
tumor, was significantly lowered either by ASNase, alone or in combination, 
but not by MSO alone (Fig. 67). 
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Fig. 64 ASNase and MSO reduced HC-AFW1 tumor mass. NSG mice 
were s.c. engrafted with HC-AFW1 cells. After 2 weeks, mice (n=5 for 
treated groups; n = 4 for controls) were i.p. injected with ASNase and/or 
MSO. After 10 days of treatment, mice were sacrificed, and tumors were 
explanted and weighted. One-way ANOVA analysis was performed and p 
values are shown. This experiment was performed at Univesity of Tübingen 
by the group of Prof. Armeanu-Ebinger. 
 
 
Fig. 65 Explanted HC-AFW1 tumors. Representative pictures of dissected 
tumors. For each group, the tumor with the weight closest to the group 
mean is shown. This experiment was performed at Univesity of Tübingen 
by the group of Prof. Armeanu-Ebinger. 
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Fig. 66 ASNase and MSO delayed the growth of HC-AFW1 xenografts. 
NSG mice were s.c. engrafted with HC-AFW1 cells. After 2 weeks, mice 
(n=5 for treated groups; n = 4 for controls) were i.p. injected with ASNase 
and/or MSO. After 10 days of treatment, mice were sacrificed, and tumors 
were explanted. Relative tumor volume was calculated as the ratio between 
the volume at sacrifice and the volume at the beginning of treatments. One-
way ANOVA analysis was performed and p values are shown. This 
experiment was performed at Univesity of Tübingen by the group of Prof. 
Armeanu-Ebinger. 
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Fig. 67 ASNase alone or in combination lowered Ki76 index. NSG mice 
were s.c. engrafted with HC-AFW1 cells. After 2 weeks, mice (n=5 for 
treated groups; n = 4 for controls) were i.p. injected with ASNase and/or 
MSO. After 10 days of treatment, mice were sacrificed, tumors were 
explanted, and Ki67 positivity of tumors was assessed as described in 
Methods. A single representative field for each condition is shown (40x). 
Ki67 index was calculated as described in Methods. One-way ANOVA 
analysis was performed and p values are shown. This experiment was 
performed at Univesity of Tübingen by the group of Prof. Armeanu-Ebinger. 
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These results clearly show that, when assayed in vivo, HC-AFW1 ASNase-
resistant HC-AFW1 cells are sensitive to Gln depletion achieved with the 
combined treatment (ASNase and MSO), which substantially reduced 
tumor growth. Interestingly, when tumor volume at sacrifice (Fig. 66) was 
matched and normalized to the tumor size at the beginning of the 
treatments, both drugs used alone also showed significant effects on tumor 
growth. Thus, apparently, HC-AFW1 cells seem more sensitive to Gln 
depletion in vivo than in vitro. This paradox may be explained considering 
that the extracellular concentration of glutamine is markedly higher in the 
culture medium (2 mM for HC-AFW1 cells) than in serum (about 0.6 mM, 
unpublished observation).  
 
In conclusion, we demonstrated that glutaminoytic treatment may be 
considered a useful tool for the control of HCC, a pathology characterized 
by poor prognosis, low sensitivity to chemotherapy, and high recurrence. 
Since the β-catenin-mutated HC-AFW1 HCC cells, which are resistant to 
ASNase in vitro, are sensitive to ASNase and, even more, to ASNase and 
MSO in vivo, it is possible to conclude that, at least in β-catenin-mutated 
tumor, this treatment is effective under experimental set. Given that 
ASNase is a drug already in use in clinic, being one of the keystones of 
acute lymphoblastic leukaemia treatment, these results may open the path 
to assess ASNase use in HCC in clinical trials.  
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4.2.2 “GS negative” human oligodendroglioma (OD) cell lines 
are extremely sensitive to glutamine depletion 
We have demonstrated that GS-expressing HCC lines are sensitive to 
ASNase treatment. Moreover, the line HC-AFW1, which expresses the 
highest GS expression, is resistant to ASNase in vitro. This result points to 
a protective role for GS expression/activity in ASNase-treated cells. If this is 
the case, a fortiori the drug should be effective in tumors which express low 
levels of Glutamine Synthetase.  
Oligodendroglioma (OD) is a rare form of glioma originating from 
oligodendrocytes. In vivo, OD is characterized by low expression of GS, 
which is a distinctive trait for discriminate OD from astrocytoma [164]. 
Therefore, we decided to test ASNase effects also in OD cell lines.  
 
4.2.2.1 In Hs683 and HOG, two OD lines, GS is under detection 
limits 
First of all, GLUL mRNA expression and GS protein abundance were 
measured in Hs683 and HOG, two human OD cell lines. For positive 
control the human glioma cell line U87 was used. We observed that, 
compared to U87, OD cell lines expressed much lower GLUL levels (Fig. 
68). Furthermore at protein level GS, although it was under detection limits 
in all the cell lines, was stabilized only in ASNase treated U87 cells, but not 
in HOG or in Hs683 cells (Fig. 69), thus confirming that these models can 
be considered “GS negative”.  
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Fig. 68 HOG and Hs683 cells express very low levels of GLUL. GLUL 
expression was analyzed by RT-qPCR. Cells were incubated in standard 
growth medium. Relative GLUL mRNA abundance was normalized to RPL-
15 and expressed as Arbitrary Units. 
 
 
 
 
Fig. 69 “GS-negative” OD cell lines did not induce GS after ASNase 
treatment. Western Blot of GS was performed in HOG, Hs683, and U87 
cells incubated with 1 U/ml ASNase (+) or in standard growth medium (-). 
β-tubulin was used as a loading control. The experiment was repeated 
three times with comparable results. 
 
 - 137 - 
4.2.2.2 “GS-negative” OD cell lines are extremely sensitive to 
glutamine depletion.  
HOG, Hs683 and U87 cells were incubated with decreasing concentration 
of ASNase (from 1 to 0.001 U/ml) in the absence or in the presence of 1 
mM MSO. From the dose-response curve it was possible to notice that both 
the OD cell lines were extremely sensitive to Gln depletion caused by 
ASNase, with an IC50 of, approximately, 0.03 U/ml (Fig. 70), lower than 0.1 
U/ml, which is considered the threshold sensibility concentration in 
leukaemia cells. In OD cells, MSO did not cause an increase in toxicity, as 
expected for cells lacking GS activity. Instead, in U87 cells IC50 for ASNase 
was about 0.2 U/ml, thus higher than 0.1 U/ml, and MSO supplementation 
lowered ASNase IC50 to 0.06 U/ml (Fig. 70).  
Consistently, the microscopic observation of HOG, Hs683 and U87 cells 
revealed massive cell death in OD cells treated with the ASNase (1 U/ml) 
and no difference between ASNase alone or in combination with MSO (Fig. 
71), while in U87 cells MSO clearly enhances ASNase effects. These 
results support the hypothesis that GS is involved in the adaptation to 
ASNase treatment.  
ASNase treatment, hydrolyzing Gln produces equimolar Glu and 
ammonium. Given that it has been demonstrated that Glu may cause 
excitotoxicity and, consequently, oligodendrocyte cell death [165], HOG, 
Hs683 and U87 were treated with 2 mM of Glu, so as to ascertain if Glu is 
involved in ASNase effects. No toxic effects of Glu in cell viability was 
detected in all the cell lines (Fig. 72), confirming that the toxicity of ASNase 
is not attributable to elevated extracellular Glu concentration.  
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Fig. 70 MSO synergized 
ASNase effects only in 
GS expressing cells. 
HOG, Hs683, and U87 cells 
were incubated with 
different ASNase 
concentrations (1, 0.3, 0.1, 
0.03, 0.01, 0.003, 0.001 
U/ml) in the absence or in 
the presence of 1 mM 
MSO. After 48 hours cells 
were incubated with 
resazurin and viability was 
assessed. Data are 
expressed as % of viability 
determined in untreated 
cells. Means ± SD of three 
experiments with four 
determinations each, are 
shown. IC50 was calculated 
with non-linear regression 
curve fit software.  
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Fig. 71 MSO synergized ASNase effects only in GS expressing cells. 
Microscopic observation of HOG, Hs683 and U87 cells treated with 
ASNase (1 U/ml) alone or in combination with MSO (1 mM). A single 
representative field is shown for each condition. Magnification 200x. 
 
 - 140 - 
 
Fig. 72 No glutamate toxicity effect was detected. HOG, Hs683 and U87 
cells were treated with ASNase (1 U/ml) or in absence of Gln (-Gln) or in 
presence of both Gln and 2 mM Glu (+Glu). After 48 hours viability was 
assessed and data expressed as % of cells incubated in standard growth 
medium. Means ± SD of four independent determinations are shown. *** p 
< 0.001 vs. control.  
 
 
Oligodendrogliomas, although rare and slow-growing cancers, are 
generally more sensitive to chemotherapy than other gliomas, but 
recurrences are possible [166]. 
The translational impact of these findings fully deserves, therefore, further 
investigations.  
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4.2.3 Mesenchymal stem cells are involved in ASNase 
resistance 
L-Asparaginases of bacterial origin have been used in acute lymphoblastic 
leukaemia (ALL) treatment since early 70s and have dramatically improved 
the prognosis of this form of infantile cancer. Although survival in childhood 
ALL is now approaching 90%, some subsets still have an adverse 
prognosis [128], and resistance-associated relapse, usually due to immune- 
and non-immune mechanisms, is frequently observed.  
It has been demonstrated that, after multiple ASNase administrations, 
patients develop antibodies against ASNase [167]. To circumvent the 
immune response, ASNase is changed from the E. coli native product to its 
pegylated form or, eventually, to E. chysantemi enzyme. Relapse, however, 
may be exacerbated and correlated with the up-regulation of the Gln-
dependent enzyme ASNS [62], while the role of GS has not been yet 
evaluated. However, if Gln depletion plays a role in ASNase anti-leukemic 
effect, the E. chysantemi enzyme is to be preferred since it has an higher 
glutaminase activity than E. coli ASNase [61].  
Recently it has been proposed that a trophic role of bone marrow 
mesenchymal stem cells (MSC) may be involved in ASNase resistance and 
leukaemia relapse in ALL [66, 71]. According to this theory, bone marrow 
MSC form a niche and release Asn to feed the leukemic blasts, thus 
preserving them from ASNase effects. However, no data are yet available 
on ASNase effects on MSC themselves.  
 
4.2.3.1 MSC are relatively insensitive to ASNase treatment 
A time course experiment showed that MSC, obtained from the bone 
marrow of two donors, initially arrested proliferation in the presence of 
ASNase or of ASNase and MSO (Fig. 73). However, a partial restoration of 
viability was observed in cells treated with ASNase after 72 hours. On the 
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contrary, no rescue of viability was observed with ASNase and MSO (Fig. 
73) suggesting that GS plays a role in counteracting ASNase effects. MSO 
alone was without significant effects. Results were corroborated by 
microscopic observation (Fig. 74).  
 
 
Fig. 73 MSC rescue proliferation two days after ASNase 
administration. MSC were incubated in DMEM with ASNase (1 U/ml, 
alone or in presence of 1 mM MSO) or MSO alone. Control cells were 
maintained in standard growth medium. Viability was assessed with 
resazurin at t=0 and after 2 and 3 days of treatments. Data are expressed 
as % of t=0 for each condition. Means of four independent determinations ± 
SD are shown. *p<0.05 vs. 2d-ASNase-treated cells.  
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Fig. 74 ASNase delays MSC cell proliferation. MSC were incubated in 
DMEM with ASNase (1 U/ml, alone or in the presence of 1 mM MSO) or 
MSO alone. Control cells were maintained in standard growth medium. 
Cells were photographed after 72 hours treatments. Magnification 100x.  
 
Consistently, the IC50 of ASNase in MSC was higher than 10 U/ml (Fig. 75) 
and adding MSO to ASNase, although decreased ASNase IC50 to 0.25 ± 
0.04, did not severely affect cell viability. Comparable results were obtained 
from the two different donors (Fig. 75), and therefore intrinsic biological 
variability could be excluded. Moreover, when MSC were incubated in 
media supplemented with different Gln concentrations, they confirm their 
limited sensitivity to Gln depletion. Significant changes are observed only 
when cells were cultivated in absence of Gln (not shown). Furthermore, 
when the time course experiment was prolonged to 6 days, it was clearly 
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evident that ASNase treated cell population had significantly grown (Fig. 
76), suggesting that MSC are able to successfully adapt to Gln starvation. 
MSO prevented MSC adaptation and, in fact, cell number decreased (Fig. 
76), suggesting that this condition caused cell death and that GS may be 
directly involved in the adaptation process.  
 
 
Fig. 75 MSC were not sensitive to ASNase. MSC from two different 
donors (MSC I and MSC II) were incubated in DMEM with decreasing 
concentrations of ASNase (from 10 to 0.003 U/ml) alone or in the presence 
of MSO (1 mM). Control cells were maintained in standard growth medium. 
After 48 hours viability was assessed with resazurin. Data are expressed as 
% of control. Means ± SD are shown. IC50 was calculated with a non-linear 
regression curve fit.  
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Fig. 76 MSC successfully adapt to ASNase. MSC were incubated in 
DMEM with ASNase (1U/ml, in the presence or in the absence of 1 mM 
MSO) or with MSO alone. Control cells were maintained in 
unsupplemented growth medium. Cells were counted at t=0 on every day of 
treatment. Data are expressed as % of cell number at t=0. Means ± SD are 
shown. *p<0.05 compared to t=0.  
 
4.2.3.2 MSC adapt to ASNase through the induction of GS and 
autophagy 
What are the molecular mechanisms involved in adaptation to ASNase-
imposed nutritional stress in MSC cells? A 2-fold transient induction of 
ASNS and SLC38A2 (encoding for the transporter SNAT2) genes was 
observed in both ASNase and ASNase and MSO treated cells (Fig. 77), 
while no statistical difference in GLUL or in SLC1A5 (encoding for the 
transporter ASCT2) mRNA expression was detected. These results 
suggest that Gln depletion caused the phosphorylation of eIF2α (as 
confirmed by Western blot analysis, see Fig. 78) with the activation of 
activating transcription factor (ATF4) and, subsequently, the expression of 
its downstream targets ASNS and SNAT2 [150, 156].  
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Furthermore mTORC1 activity, assessed as the phosphorylation of the 
downstream target S6K1 at residue T389, was decreased by ASNase at 
earlier times (from 3 to 9 hours of treatment), but increased, reaching levels 
even higher than control, after 48 hours of ASNase treatment. Consistently, 
autophagy, a catabolic process directly down-regulated by mTOR [45] and 
assessed through the accumulation of the lipidated LC3 protein (LC3 II), 
was induced after 6 hours, reached the maximum at 24 hours, and 
decreased after 48 hours of ASNase treatment (Fig. 78).  
MSO yielded apparently paradoxical results, which, however, are fully 
consistent with the results described in 4.1.3 Glutamine Synthetase 
inhibitors activate mTORC1 paragraph. Moreover, GS protein was 
stabilized by treatments in a time-dependent manner (Fig. 78). Similar 
results were obtained in cells incubated in the absence of Gln (not shown).  
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Fig. 77 MSC induced ASNS and the SNAT2 transporter after 
treatments. ASNS (A), GLUL (B), SLC38A2 (C), and SLC1A5 (D) 
expression was analyzed by RT-qPCR. MSC (from two donors) were 
incubated with ASNase (A) or ASNase and MSO (AM) for the indicated 
times. Control cells were maintained in standard growth medium. ASNS 
(A), GLUL (B), SLC38A2 (C) and SLC1A5 (D) mRNA abundance was 
normalized to RPL-15 and expressed as Arbitrary Units. Means ± SD of 
three experiments with two determinations each are shown. **p<0.01 
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Fig. 78 Autophagy and GS induction were responsible of ASNase-
induced Gln depletion. Western Blot of eIF2α (phospho S51), S6K1 
(phospho T389), LC3 II, and GS was performed in MSC incubated with 
ASNase (A), ASNase and MSO (AM) or in standard growth medium for 
control (C). GAPDH was used as a loading control. The experiment was 
repeated three times with MSC from two donors with comparable results. 
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Fig. 79 CHOP induction is transient in ASNase treated MSC. CHOP 
expression was analyzed by RT-qPCR. MSC were incubated with ASNase 
(A) or ASNase and MSO (AM) for the indicated times. CHOP mRNA 
abundance was normalized to RPL-15 and expressed as Arbitrary Units. 
Means ± SD of three experiments with two determinations each are shown. 
**p<0.01 vs. control, § p<0.05 v cells treated with ASNase for 6 hours  
 
The expression of the mRNA for the pro-apoptotic protein CHOP was also 
evaluated by qPCR. As shown in Fig. 79, CHOP mRNA was already 
significantly increased after 3 hours treatment. However, while in ASNase 
and MSO treated cells CHOP induction was sustained up to 24 hours, 
without MSO was transient (Fig. 79), consistently with the successful 
adaptation to the Gln-depleting agent.  
Thus, since MSO inhibits GS but also causes abnormal mTOR activation 
with a consequent delay of the autophagic response, both GS and 
autophagy may contribute to MSC adaptation to ASNase. These results 
may strengthen the hypothesis that a release of Asn and Gln by MSC feed 
leukemic blasts in a confined niche in the bone marrow compartment during 
ASNase treatment.  
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4.2.3.3 MSC protect ALL blast from ASNase treatment 
To verify the protective role of MSC, ALL cell lines RS4;11, REH, and 
Nalm6 were treated with decreasing ASNase concentration. Viability assay 
revealed the extreme sensitivity of these cells to ASNase with IC50 of 
3.21*10-04 ± 3,35*10-05 U/ml for RS4;11, 0.008 ± 0.002 U/ml for REH and 
0.04 ± 0.02 U/ml for Nalm6 (Fig. 80). This different sensitivity seems to be 
correlated to ASNS gene expression which is barely detectable in RS4;11 
and highest in Nalm6 (not shown), although it has been demonstrated that 
low ASNS expression does not always predict high ASNase sensitivity 
[168].  
Incubating ALL cells in the absence of Gln revealed only a partial sensitivity 
to Gln starvation in REH and RS4;11, while Nalm6 cells viability was not 
affected at all (Fig. 81). Thus, it is likely that the loss of viability caused by 
ASNase in these cell lines is mainly due to the lack of Asn.  
Then, a preliminary co-culture experiment was set. The most sensitive 
RS4;11 and REH cells were treated with ASNase (at the IC50 concentration 
each) alone or in combination with 1 mM MSO, in the presence of a feeder 
layer of MSC. After 48 hours of treatment it was clear that MSC protected 
ALL cells from ASNase treatment (Fig. 82). The protective effect of MSC 
was still detectable in the presence of MSO (Fig. 82).  
 
From these results it is possible to conclude that mesenchymal stem cells 
do adapt to ASNase and effectively protect ALL blast from this drug.  
Indeed while MSO prevents MSC adaptation to ASNase, through the 
inhibition of both GS and autophagy, it do not avoid MSC trophic interaction 
with ALL blasts, suggesting that other mechanisms are involved. However, 
further experiments need to unveil the complex interaction between MSC 
and ALL blasts.  
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Fig. 80 ALL cell 
lines were 
extremely sensitive 
to ASNase. RS4;11, 
REH, and Nalm6 
were incubated in 
RPMI with different 
concentrations of 
ASNase (from 1 to 
0.0001 U/ml). Control 
cells were maintained 
in standard growth 
medium. After 48 
hours viability was 
assessed with 
resazurin. Data are 
expressed as % of 
control. Means of 
three different 
experiments with six 
independent 
determinations each 
± SD are shown. IC50 
was calculated with a 
non-linear regression 
curve fit.  
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Fig. 81 Gln starvation only partially affects ALL cell line viability. 
RS4;11, REH, and Nalm6 were incubated in RPMI with or without 2 mM 
Gln. After 48 hours viability was assessed with resazurin. Data are 
expressed as % of control. Means of six independent determinations in a 
single experiment are shown ± SD. 
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Fig. 82 MSC protected ALL lines from ASNase and ASNase and MSO. 
MSC were seeded and incubated in standard growth medium for 48 hours. 
RS4;11 and REH were added to the feeder layer or on plastic and 
incubated in RPMI with ASNase (A) or ASNase and MSO (AM). ASNase 
was used at the IC50 of each cell lines. After 48 hours cells were stained for 
PI and flow cytometry was assessed. Data are expressed as viability in % 
of each control. A single preliminary experiment is shown. 
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CHAPTER 5 
CONCLUSIONS 
In conclusion, the results obtained show that glutamine plays an important 
role in promoting both cell growth and mTOR activation. Moreover, non 
proteinogenic amino acids, which are analogs of glutamine and inhibitors of 
Glutamine Synthetase (GS), are also able to activate mTOR, indicating that 
not only essential amino acids regulate the kinase.  
As far as the possibility of targeting glutamine metabolism in human 
hepatocellular carcinoma (HCC) is concerned, we have demonstrated that 
pharmacologically-induced glutamine depletion, obtained with the bacterial 
enzyme L-asparaginase (ASNase) and the GS inhibitor MSO, markedly 
hinder β-catenin-mutated HCC cell proliferation not only in vitro but also in 
xenograft models.  
These results suggest that the combination of extracellular Gln depletion 
with the inhibition of intracellular glutamine synthesis causes a severe 
metabolic stress, which leads to liver cancer cell death (Fig. 83). Moreover, 
this is the first evidence of antitumor activity of a GS inhibitor and suggests 
that a glutamine-depleting treatment may be relevant for the therapy of 
hepatocellualar carcinoma, a cancer which still has a poor prognosis. 
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Fig. 83 ASNase and MSO mechanism of action. 
 
However, the hyper-expression of GS may be considered a defense 
against glutamine shortage, as demonstrated a contrariis by the synthetic 
lethality observed in ASNase-treated GS-negative human 
oligodendroglioma in vitro, a result worthy of a confirmation with in vivo 
models. Lastly, the combination of ASNase and MSO may also hinder the 
recently described nutritional interaction between bone marrow stromal 
cells and leukemic blasts. Indeed, stromal cells adapt to ASNase through 
GS induction and autophagy triggering, mechanisms both prevented by 
MSO.  
 
In summary, interference with Gln metabolism and, in particular, with GS 
activity may constitute a useful approach for the control of selected human 
cancers.  
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